

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LUKASHEV *et al.*

Appl. No.: To be assigned

(Continuation of Appl. No. 12/526,296;
§ 371(c) Date: January 13, 2011)

Filed: Herewith

For: **Treatment for Multiple Sclerosis
(As Amended)**

Confirmation No.: *To be assigned*

Art Unit: *To be assigned*

Examiner: *To be assigned*

Atty. Docket: 2159.3210002/JMC/MRG/U-S

First Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms PTO/SB/08a equivalent and/or PTO/SB/08b equivalent are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

Applicants have checked the appropriate boxes below.

- 1. Statement under 37 C.F.R. 1.704(d). Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 2. Filing under 37 C.F.R. § 1.97(b). This Information Disclosure Statement is being filed within three months of the date of filing of a national application other than a continued prosecution application (CPA), OR within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, OR before the mailing date of a first Office Action on the merits OR before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

3. Filing under 37 C.F.R. § 1.97(c). This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application.
- a. Statement under 37 C.F.R. § 1.97(e)(1). I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
- b. Statement under 37 C.F.R. § 1.97(e)(2). I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- c. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

4. Filing under 37 C.F.R. § 1.97(d) This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Enclosed find our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p); in addition:
- a. Statement under 37 C.F.R. § 1.97(e)(1). I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
 - b. Statement under 37 C.F.R. § 1.97(e)(2). I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
5. The document(s) was/were cited in a search report by a foreign patent office in a counterpart foreign application. Submission of an English language version of the search report that indicates the degree of relevance found by the foreign office

is provided in satisfaction of the requirement for a concise explanation of relevance. 1138 OG 37, 38 and MPEP 609.04(a)(III).

6. A concise explanation of the relevance of the non-English language documents appears below in accordance with 37 C.F.R. § 1.98(a)(3).

Document **FP1, JP 54-80439 A**, is in the Japanese language. An English language abstract of document FP1 is cited as document **NPL1** and submitted herewith.

Document **FP2, EP 0 188 749 A2**, is in the German language. Document **US3** is believed to be an English-language equivalent of document FP2.

Document **FP4, EP 0 312 697 A2**, is in the German language. Document **US4** is believed to be an English-language equivalent of document FP4.

Document **FP5, DE 38 34 794 A1**, is in the German language. An English language abstract of document FP5 is cited as document **NPL2** and submitted herewith.

Document **FP6, EP 0 518 388 A2**, is in the German language. Document **US4** is believed to be an English-language equivalent of document FP6.

Document **FP7, JP 6-345644 A**, is in the Japanese language. An English language abstract of document FP7 is cited as document **NPL3** and submitted herewith.

Document **FP9, JP 8-99906 A**, is in the Japanese language. An English language abstract of document FP9 is cited as document **NPL4** and submitted herewith.

Document **FP13, JP 9-221428 A**, is in the Japanese language. An English language abstract of document FP13 is cited as document **NPL5** and submitted herewith.

Document **FP15, WO 97/48405 A1**, is in the Russian language. An English language abstract of document FP15 is cited as document **NPL6** and submitted herewith.

Document **FP19, DE 197 21 099 A1**, is in the German language. Document **US14** is believed to be an English-language equivalent of document FP19.

Document **FP23, RU 2 189 813 C1**, is in the Russian language. An English language abstract of document FP23 is cited as document **NPL7** and submitted herewith.

Document **FP25, WO 2005/027899 A1**, is in the German language. An English language abstract of document FP25 is cited as document **NPL8** and submitted herewith.

Document **FP37, CN 1125141 A**, is in the Chinese language. An English language abstract of document FP37 is cited as document **NPL292** and submitted herewith.

Document **NPL28, Dücker and Pfeiff**, is in the German language. An English language abstract of document NPL28 can be found on the face page of the publication.

Document **NPL31, Fliegner and Spiegel**, is in the German language. An English language abstract of document NPL31 can be found on the face page of the publication.

Document **NPL48, Hunziker and Schmidli**, is in the German language. It is believed that document **NPL47** is a partial English language translation of document NPL48.

Document **NPL163, Gutzmer *et al.***, is in the German language. An English language abstract of Document NPL163 is cited as document **NPL164** and submitted herewith.

Document **NPL165, Hagedorn *et al.***, is in the German language. An English language abstract of document NPL165 can be found on the face page of the publication.

Document **NPL187, Roodnat *et al.***, is in the German language. An English language abstract of document NPL187 can be found on the face page of the publication.

Document **NPL191, Schilling and Schopf**, is in the German language. An English language abstract of document NPL191 can be found on the face page of the publication.

Document **NPL198**, **Van Loenen *et al.***, is in the Dutch language. An English language abstract of document NPL198 can be found on the face page of the publication.

Document **NPL202**, **Wanscher and Sørensen**, is in the Danish language. An English language abstract of document NPL202 can be found on the page 6357 of the publication.

Document **NPL210**, *Immunmodulation durch Fumaderm. Das richtungsweisende Konzept*, is in the German language. It is believed that document **NPL211** is a partial English language translation of document NPL210.

Document **NPL215**, **Bayard *et al.***, is in the German language. An English language abstract of document NPL215 can be found on the face page of the publication.

Document **NPL234**, "Klinische Studie mit Fumaderm® als magensaftresistente Mikrotabletten," the first three pages are in the German language. An English language translation of pages 1-3 of document NPL234 can be found on pages 4-6 of the same document.

Document **NPL247**, **Peeters *et al.***, is in the Dutch language. An English language abstract of document NPL247 can be found on the last page of the publication.

Document NPL257, **Stangel *et al.***, is in the German language. An English language abstract of document NPL257 can be found on page 215 of the publication.

Document NPL258, **Stühlinger *et al.***, is in the German language. An English language abstract of document NPL258 can be found on the face page of the publication.

- 7. Copies of the documents are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), no copies of U.S. patents and patent application publications cited as documents US1-US40 on the attached IDS Forms are submitted.
- 8. Copies of documents FP1-FP50 and NPL1-NPL293 were cited by or submitted to the Office in an IDS that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 12/526,296, with a § 371(c) date of January 13, 2011, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).
- 9. It is expected that the examiner will review the prosecution and cited art in the parent application no. 12/526,296 in accordance with MPEP 2001.06(b), and indicate in the next communication from the office that the art cited in the earlier prosecution history has been reviewed in connection with the present application.
- 10. In accordance with the Federal Circuit decision in *Dayco Prods., Inc. v. Total Containment, Inc.* 329 F.3d 1358 (Fed. Cir. 2003), Applicants submit herewith Office Actions from the co-pending U.S. Patent Application Nos. 09/194,862, §

371(c) date July 8, 1999; 09/402,103, § 371(c) date September 27, 1999; 09/743,978, § 371(c) date January 17, 2001; 09/831,620, § 371(c) date May 10, 2001; 10/148,858, § 371(c) date May 28, 2002; 10/197,077, filed July 17, 2002; 11/765,563, filed June 20, 2007; 11/765,578, filed June 20, 2007; 12/405,661, filed March 17, 2009; and 12/405,665, filed March 17, 2009, as documents **NPL269-NPL291**.


The identification of these Office Actions is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Marsha A. Rose
Attorney for Applicants
Registration No. 58,403

Date: 2/13/2012

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

1476774_1.DOCX

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
Sheet	1	of	7	Attorney Docket Number	2159.3210002/JMC/MRG/U-S

U.S. PATENT DOCUMENTS						
Examiner initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
	US1	4,515,974		05-07-1985	Zecher <i>et al.</i>	
	US2	4,746,668		05-24-1988	Sato <i>et al.</i>	
	US3	4,851,439		07-25-1989	Speiser <i>et al.</i>	
	US4	4,959,389		09-25-1990	Speiser <i>et al.</i>	
	US5	5,149,695		09-22-1992	Speiser <i>et al.</i>	
	US6	5,214,196		05-25-1993	Blank	
	US7	5,242,905		09-07-1993	Blank	
	US8	5,359,128		10-25-1994	Blank	
	US9	5,424,332		06-13-1995	Speiser <i>et al.</i>	
	US10	5,451,667		09-19-1995	Speiser <i>et al.</i>	
	US11	6,277,882 B1		08-21-2001	Joshi <i>et al.</i>	
	US12	6,355,676 B1		03-12-2002	Joshi <i>et al.</i>	
	US13	6,359,003 B1		03-19-2002	Joshi <i>et al.</i>	
	US14	6,436,992 B1		08-20-2002	Joshi <i>et al.</i>	
	US15	6,509,376 B1		01-21-2003	Joshi <i>et al.</i>	
	US16	6,858,750 B2		02-22-2005	Joshi <i>et al.</i>	
	US17	7,157,423 B2		01-02-2007	Joshi <i>et al.</i>	
	US18	7,320,999 B2		01-22-2008	Joshi <i>et al.</i>	
	US19	7,432,240 B2		10-07-2008	Joshi <i>et al.</i>	
	US20	7,612,110 B2		11-03-2009	Joshi <i>et al.</i>	

FOREIGN PATENT DOCUMENTS							
Examiner initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
	FP1	JP 54-80439 A		06-27-1979	Ogawa Hiroe		
	FP2	EP 0 188 749 A2		07-30-1986	Speiser <i>et al.</i>		
	FP3	WO 89/01930 A1		03-09-1989	Dexter Biotechnics		
	FP4	EP 0 312 697 A2		04-26-1989	Speiser <i>et al.</i>		
	FP5	DE 38 34 794 A1		04-19-1990	Schielein, F.		
	FP6	EP 0 518 388 A2		12-16-1992	Speiser <i>et al.</i>		
	FP7	JP 6-345644 A		12-20-1994	Unitika Ltd.		
	FP8	WO 94/28883 A1		12-22-1994	Brown, Raymond		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO			Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	<i>To be assigned</i>
			Filing Date	Herewith
			First Named Inventor	Matvey E. LUKASHEV
			Art Unit	<i>To be assigned</i>
			Examiner Name	<i>To be assigned</i>
			Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	2	of	7	

U.S. PATENT DOCUMENTS						
Examiner initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
	US21	7,619,001	B2	11-17-2009	Joshi <i>et al.</i>	
	US22	7,790,916	B2	09-07-2010	Joshi <i>et al.</i>	
	US23	7,803,840	B2	09-28-2010	Joshi <i>et al.</i>	
	US24	7,915,310	B2	03-29-2011	Joshi <i>et al.</i>	
	US25	2004/0054001	A1	03-18-2004	Joshi <i>et al.</i>	
	US26	2008/0233185	A1	09-25-2008	Joshi <i>et al.</i>	
	US27	2010/0130607	A1	05-27-2010	Gold	
	US28	5,538,968		07-23-1996	Chiesi <i>et al.</i>	
	US29	5,548,059		08-20-1996	Bayley <i>et al.</i>	
	US30	5,972,363		10-26-1999	Clikeman <i>et al.</i>	
	US31	6,812,248	B2	11-02-2004	Zhang <i>et al.</i>	
	US32	7,056,950	B2	06-06-2006	Rath	
	US33	7,279,331	B2	10-09-2007	Black <i>et al.</i>	
	US34	7,364,900	B2	04-29-2008	Black <i>et al.</i>	
	US35	7,417,045	B2	08-26-2008	Anilkumar <i>et al.</i>	
	US36	7,638,119	B2	12-29-2009	Johnson <i>et al.</i>	
	US37	7,871,977	B2	01-18-2011	Rischer <i>et al.</i>	
	US38	2003/0176365	A1	09-18-2003	Blass	
	US39	2005/0245612	A1	11-03-2005	Blass	
	US40	2008/0089861	A1	04-17-2008	Went <i>et al.</i>	

FOREIGN PATENT DOCUMENTS							
Examiner initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
	FP9	JP	8-99906 A	04-16-1996	Chugai Pharmaceutical Co., Ltd.		
	FP10	WO	97/09984 A1	03-20-1997	Takeda Chemical Industries, Ltd.		
	FP11	WO	97/13504 A1	04-17-1997	Medgene Limited		
	FP12	CA	2,248,955 A1	05-20-1997	Fumapharm AG		
	FP13	JP	9-221428 A	08-26-1997	Fujisawa Pharmaceutical Co.		
	FP14	WO	97/44054 A2	11-27-1997	University of Alberta		
	FP15	WO	97/48405 A1	12-24-1997	Belyaev, Jury Evgenievich		
	FP16	WO	98/04290 A2	02-05-1998	Perrine <i>et al.</i>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	1	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	Thomson Innovation Patent Record, DWPI Accession No. 1979-58797B, English language Abstract of Japanese Patent Publication No. 54-80439 A, (1979)	Abs.
	NPL2	English language Abstract of German Patent Publication No. DE 38 34 794 A1, European Patent Office, Espacenet database — Worldwide (2001)	Abs.
	NPL3	English language Abstract of Japanese Patent Publication No. JP 6-345644 A, European Patent Office, Espacenet database — Worldwide (2001)	Abs.
	NPL4	English language Abstract of Japanese Patent Publication No. JP 8-99906 A, European Patent Office, Espacenet database — Worldwide (2001)	Abs.
	NPL5	English language Abstract of Japanese Patent Publication No. JP 9-221428 A, European Patent Office, Espacenet database — Worldwide (2001)	Abs.
	NPL6	English language Abstract of WIPO Patent Publication No. WO 97/48405 A1, European Patent Office, Espacenet database — Worldwide (2001)	Abs.
	NPL7	English language Abstract of Russian Patent Publication No. RU 2 189 813 C1, European Patent Office, Espacenet database — Worldwide (2002)	Abs.
	NPL8	English language Abstract of WIPO Patent Publication No. WO 2005/027899 A1, European Patent Office, Espacenet database — Worldwide (2005)	Abs.
	NPL9	ALTMAYER, P.J., <i>et al.</i> , "Antipsoriatic effect of fumaric acid derivatives <i>Results of a multicenter double-blind study in 100 patients</i> ," <i>Journal of the American Academy of Dermatology</i> 30(6):977-981, American Academy of Dermatology, Inc., United States (1994)	
	NPL10	ANDERSSON, M., <i>et al.</i> , "Cytokine profile in interferon- β treated multiple sclerosis patients: reduction of interleukin-10 mRNA expressing cells in peripheral blood," <i>Eur. J. Neurol.</i> 4:567-571, Rapid Science Publishers, England (1997)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	2	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL11	BACHARACH-BUHLES, M., <i>et al.</i> , "Fumaric Acid Esters (FAEs) Suppress CD 15- and ODP 4-positive Cells in Psoriasis," <i>Acta. Derm. Venereol. Suppl. (Stockh)</i> 186:79-82, Scandinavian University Press, Norway (1994)	
	NPL12	BALASHOV, K.E., <i>et al.</i> , "Defective regulation of IFN γ and IL-12 by endogenous IL-10 in progressive MS," <i>Neurology</i> 55:192-198, AAN Enterprises, Inc., United States (2000)	
	NPL13	BECANOVIC, K., <i>et al.</i> , "Paradoxical effects of arthritis-regulating chromosome 4 regions on myelin oligodendrocyte glycoprotein-induced encephalomyelitis in congenic rats," <i>Eur. J. Immunol.</i> 33:1907-1916, WILEY-VCH Verlag GmbH & Co. KGaA, Germany (2003)	
	NPL14	BETTELLI, E. and NICHOLSON, L.B., "The Role of Cytokines in Experimental Autoimmune Encephalomyelitis," <i>Arch. Immun. Ther. Exp.</i> 48:389-398, Warszawa, Panstwowy Zakład Wydawn Lekarskich, Switzerland (2000)	
	NPL15	BROWN, T.R. and KRAFT, G.H., "Multiple Sclerosis: A Paradigm Shift," <i>Phys. Med. Rehabil. Clin. N. Am.</i> 16:xvii-xx, Elsevier Inc., United States (2005)	
	NPL16	CANNELLA, B., <i>et al.</i> , "IL-10 Fails to Abrogate Experimental Autoimmune Encephalomyelitis," <i>J. Neuroscience Research</i> 45:735-746, Wiley-Liss, Inc., United States (1996)	
	NPL17	CORREALE, J., <i>et al.</i> , "Sulfasalazine aggravates experimental autoimmune encephalomyelitis and causes an increase in the number of autoreactive T cells," <i>J. Neuroimmunol.</i> 34:109-120, Elsevier Science Publishers B.V., Netherlands (1991)	
	NPL18	DAHLMAN, I., <i>et al.</i> , "Quantitative trait loci disposing for both experimental arthritis and encephalomyelitis in the DA rat; impact on severity of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis and antibody isotype pattern," <i>Eur. J. Immunol.</i> 28:2188-2196, WILEY-VCH Verlag GmbH, Germany (1998)	
	NPL19	DAL CANTO, R.A., <i>et al.</i> , "Local Delivery of TNF by Retrovirus-Transduced T Lymphocytes Exacerbates Experimental Autoimmune Encephalomyelitis," <i>Clinical Immunol.</i> 90(1):10-14, Academic Press, United States (1999)	
	NPL20	DE GRAAF, K.L., <i>et al.</i> , "MHC Class II Isotype- and Allele-Specific Attenuation of Experimental Autoimmune Encephalomyelitis," <i>J. Immunol.</i> 173:2792-2802, The American Association of Immunologists, Inc., United States (2004)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
Sheet	3	of	30
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL21	DE HAAN, P., "The Risk of Sensibilization and Contact Urticaria upon Topical Application of Fumaric Acid Derivatives," <i>Dermatology</i> 188:126-130, Karger AG, Switzerland (1994)	
	NPL22	DE JONG, R., <i>et al.</i> , "Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate," <i>Eur. J. Immunol.</i> 26:2067-2074, Verlag Chemie GmbH, Germany (1996)	
	NPL23	DEL PRETE, G., "The Concept of Type-1 and Type-2 Helper T Cells and Their Cytokines in Humans," <i>Intern. Rev. Immunol.</i> 16:427-455, OPA (Overseas Publishers Association) Amsterdam B.V., England (1998)	
	NPL24	DETHLEFSEN, L.A., "Toxic Effects of Acute Glutathione Depletion by Buthionine Sulfoximine and Dimethylfumarate on Murine Mammary Carcinoma Cells," <i>Radiation Res.</i> 114:215-224, Academic Press, Inc., United States (1988)	
	NPL25	DI MARCO, R., <i>et al.</i> , "Curative effects of recombinant human Interleukin-6 in DA rats with protracted relapsing experimental allergic encephalomyelitis," <i>J. Neuroimmunol.</i> 116:168-177, Elsevier Science B.V., Netherlands (2001)	
	NPL26	DI ROSA, F., <i>et al.</i> , "Lack of Th2 cytokine increase during spontaneous remission of experimental allergic encephalomyelitis," <i>Eur. J. Immunol.</i> 28:3893-3903, WILEY-VCH Verlag GmbH, Germany (1998)	
	NPL27	DJERBI, M., <i>et al.</i> , "Expression of the Long Form of Human FLIP by Retroviral Gene Transfer of Hemopoietic Stem Cells Exacerbates Experimental Autoimmune Encephalomyelitis," <i>J. Immunol.</i> 170:2064-2073, The American Association of Immunologists, Inc., United States (2003)	
	NPL28	DÜCKER, P. and PFEIFF, B., "Zwei Fälle von Nebenwirkungen einer Fumarsäureester - Lokaltharapie," <i>H+G Zeitschrift für Hautkrankheiten</i> 65:734-736, Grosse Verlag Berlin, Germany (1990) (Abstract Only in English)	Abs.
	NPL29	FERBER, I.A., <i>et al.</i> , "Mice with a Disrupted IFN- γ Gene Are Susceptible to the Induction of Experimental Autoimmune Encephalomyelitis (EAE)," <i>J. Immunol.</i> 156:5-7, The American Association of Immunologists, United States (1996)	
	NPL30	FERRANTE, P., <i>et al.</i> , "Cytokine Production and Surface Marker Expression in Acute and Stable Multiple Sclerosis: Altered IL-12 Production and Augmented Signaling Lymphocytic Activation Molecule (SLAM)-Expressing Lymphocytes in Acute Multiple Sclerosis," <i>J. Immunol.</i> 160:1514-1521, The American Association of Immunologists, United States (1998)	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	4	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL31	FLIEGNER, L. and SPIEGEL, P., "Osteomalazie als offenbar seltene Nebenwirkung der oralen Fumarsäuretherapie," <i>Hautarzt</i> 43:554-560, Springer-Verlag, Germany (1992) (Abstract Only in English)	Abs.
	NPL32	FURLAN, R., <i>et al.</i> , "Interferon- β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon- γ and interleukin-4," <i>J. Neuroimmunol.</i> 111:86-92, Elsevier Science B.V., Netherlands (2000)	
	NPL33	GALLI, G., <i>et al.</i> , "Macrophage-derived chemokine production by activated human T cells <i>in vitro</i> and <i>in vivo</i> : preferential association with the production of type 2 cytokines," <i>Eur. J. Immunol.</i> 30:204-210, WILEY-VCH Verlag GmbH, Germany (2000)	
	NPL34	GASSER, M., <i>et al.</i> , "Host Vs Graft and Graft Vs Host Reactions After Allogeneic Heterotopic Small Bowel Transplantation in the Rat," <i>Transplant. Proc.</i> 24(3):1128-1129, Appleton & Lange, United States (1992)	
	NPL35	GENAIN, C.P., <i>et al.</i> , "Late Complications of Immune Deviation Therapy in a Nonhuman Primate," <i>Science</i> 274:2054-2057, American Association for the Advancement of Science, United States (1996)	
	NPL36	GHORESCHI, K. and RÖCKEN, M., "Immune Deviation Strategies in the Therapy of Psoriasis," <i>Current Drug Targets - Inflammation & Allergy</i> 3:193-198, Bentham Science Publishers Ltd., Netherlands (2004)	
	NPL37	GHORESCHI, K., <i>et al.</i> , "Fumarates induce a DC2 phenotype in dendritic cells that establishes protective Th2 responses," <i>Arch. Dermatol. Forschung</i> 296:420, Springer Verlag, Germany (2005) (Abstract Only)	Abs.
	NPL38	GHORESCHI, K., <i>et al.</i> , "Fumaric acid ester an antipsoriatic drug abolishes the capacity of T cells to induce Th1-mediated autoimmune disease," <i>Arch. Dermatol. Res.</i> 294:28, Springer Verlag, Germany (2002) (Abstract Only)	Abs.
	NPL39	GIELEN, A.W., <i>et al.</i> , "Expression of T cell immunoglobulin- and mucin-domain-containing molecules-1 and -3 (TIM-1 and -3) in the rat nervous and immune systems," <i>J. Neuroimmunol.</i> 164:93-104, Elsevier B.V., Netherlands (2005)	
	NPL40	GIJBELS, K., <i>et al.</i> , "Administration of Neutralizing Antibodies to Interleukin-6 (IL-6) Reduces Experimental Autoimmune Encephalomyelitis and Is Associated with Elevated Levels of IL-6 Bioactivity in Central Nervous System and Circulation," <i>Mol. Med.</i> 1(7):795-805, Molecular Medicine, United States (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	5	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL41	GIOVANNONI, G. and MILLER, D.H., "Multiple sclerosis and its treatment," <i>J. R. Coll. Physicians Lond.</i> 33(4):315-322, Royal College of Physicians, England (1999)	
	NPL42	GUGGENMOS, J., <i>et al.</i> , "Antibody Cross-Reactivity between Myelin Oligodendrocyte Glycoprotein and the Milk Protein Butyrophilin in Multiple Sclerosis," <i>J. Immunol.</i> 172:661-668, The American Association of Immunologists, Inc., United States (2004)	
	NPL43	HEMMER, B., <i>et al.</i> , "Cytokine Phenotype of Human Autoreactive T Cell Clones Specific for the Immunodominant Myelin Basic Protein Peptide (83-99)," <i>J. Neurosci. Res.</i> 45:852-862, Wiley-Liss, Inc., United States (1996)	
	NPL44	HINTZEN, R.Q. and POLMAN, C.H., "Th-cell modulation in multiple sclerosis," <i>Immunol. Today</i> 18(10):507-508, Elsevier/North-Holland Biomedical Press, England (1997)	
	NPL45	HOHENEGGER, M., <i>et al.</i> , "Nephrotoxicity of Fumaric Acid Monoethylester (FA ME)," <i>Advances in Experimental Medicine and Biology</i> 252:265-272, Kluwer Academic, United States (1989)	
	NPL46	HULTGREN, B., <i>et al.</i> , "Genetic Absence of γ -Interferon Delays but Does Not Prevent Diabetes in NOD Mice," <i>Diabetes</i> 45:812-817, American Diabetes Association, United States (1996)	
	NPL47	English language excerpt from HUNZIKER, T. and SCHMIDLI, J., "Is Psoriasis an Autoimmune Disease?" <i>Therapeutische Umschau</i> 50:110-113, Dermatologische Klinik der Universität Bern, Switzerland (1993)	
	NPL48	HUNZIKER, T. and SCHMIDLI, J., "Psoriasis, eine Autoimmunkrankheit?" <i>Therapeutische Umschau</i> 50:110-113, Dermatologische Klinik der Universität Bern, Switzerland (1993)	
	NPL49	ISSAZADEH, S., <i>et al.</i> , "Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor α and tumor necrosis factor β ," <i>J. Neuroimmunol.</i> 61:205-212, Elsevier Science B.V, Netherlands (1995)	
	NPL50	ISSAZADEH, S., <i>et al.</i> , "Interferon γ , Interleukin 4 and Transforming Growth Factor β in Experimental Autoimmune Encephalomyelitis in Lewis Rats: Dynamics of Cellular mRNA Expression in the Central Nervous System and Lymphoid Cells," <i>J. Neurosci. Res.</i> 40:579-590, Wiley-Liss, Inc., United States (1995)	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
Sheet	6	of	30	Attorney Docket Number	2159.3210002/JMC/MRG/U-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL51	ISSAZADEH, S., <i>et al.</i> , "Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor- β ," <i>J. Neuroimmunol.</i> 69:103-115, Elsevier Science B.V., Netherlands (1996)	
	NPL52	ISSAZADEH, S., <i>et al.</i> , "Major histocompatibility complex-controlled protective influences on experimental autoimmune encephalomyelitis are peptide specific," <i>Eur. J. Immunol.</i> 27:1584-1587, VCH Verlagsgesellschaft mbH, Germany (1997)	
	NPL53	KAPPOS, L., <i>et al.</i> , "Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study," <i>Lancet</i> 372:1463-1472, Lancet Publishing Group., England (2008)	
	NPL54	KHADEMI, M., <i>et al.</i> , "Induction of systemic TNF α in Natalizumab-treated multiple sclerosis," <i>Eur. J. Neurol.</i> 15:309-312, European Federation of Neurological Sciences, England (2008)	
	NPL55	KHADEMI, M., <i>et al.</i> , "Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis," <i>J. Neuroimmunol.</i> 103:202-210, Elsevier Science B.V., Netherlands (2000)	
	NPL56	KHADEMI, M., <i>et al.</i> , "T Cell Ig- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis," <i>J. Immunol.</i> 172:7169-7176, The American Association of Immunologists, Inc., United States (2004)	
	NPL57	KIEHL, R. and IONESCU, G., "A Defective Purine Nucleotide Synthesis Pathway in Psoriatic Patients," <i>Acta Derm. Venereol. (Stockh)</i> 72:253-255, Society for the Publication of Acta Dermato-Venerologica, Sweden (1992)	
	NPL58	KJELLÉN, P., <i>et al.</i> , "Genetic influence on disease course and cytokine response in relapsing experimental allergic encephalomyelitis," <i>Int. Immunol.</i> 10:333-340, Oxford University Press, England (1998)	
	NPL59	KOLBACH, D.N. and NIEBOER, C., "Fumaric acid therapy in psoriasis: Results and side effects of 2 years of treatment," <i>J. Am. Acad. Derm.</i> 27(5):769-771, Mosby, United States (1992)	
	NPL60	KRAKAUER, M., <i>et al.</i> , "Dynamic T-lymphocyte Chemokine Receptor Expression Induced by Interferon-beta Therapy in Multiple Sclerosis," <i>Scand. J. Immunol.</i> 64:155-163, Blackwell Publishing Ltd., England (2006)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	7	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL61	KRAKOWSKI, M. and OWENS, T., "Interferon- γ confers resistance to experimental allergic encephalomyelitis," <i>Eur. J. Immunol.</i> 26:1641-1646, VCH Verlagsgesellschaft mbH, Germany (1996)	
	NPL62	KURODA, K., <i>et al.</i> , "Fumaric Acid Enhances DNA Synthesis of Rat Hepatocytes by Counteracting the Toxicities of Mitomycin C and Aflatoxin B ₁ ," <i>Jpn. J. Cancer Res. (Gann)</i> 77:750-758, Japanese Cancer Association, Japan (1986)	
	NPL63	LAFAILLE, J.J., <i>et al.</i> , "Myelin Basic Protein-specific T Helper 2 (Th2) Cells Cause Experimental Autoimmune Encephalomyelitis in Immunodeficient Hosts Rather than Protect Them from the Disease," <i>J. Exp. Med.</i> 186(2):307-312, The Rockefeller University Press, United States (1997)	
	NPL64	LAFAILLE, J.J., "The Role of Helper T Cell Subsets in Autoimmune Diseases," <i>Cytokine & Growth Factor Rev.</i> 9(2):139-151, Elsevier Science Ltd., England (1998)	
	NPL65	LAHTI, A. and MAIBACH, H.I., "Contact urticaria from diethyl fumarate," <i>Contact Dermatitis</i> 12:139-140, Munksgaard, Denmark (1985)	
	NPL66	LAMAN, J.D., <i>et al.</i> , "Balancing the Th1/Th2 concept in multiple sclerosis," <i>Immunol. Today</i> 19(11):489-490, Elsevier/North-Holland Biomedical Press, England (1998)	
	NPL67	LEHNERT, S., <i>et al.</i> , "Radiation Response of Drug-Resistant Variants of a Human Breast Cancer Cell Line: The Effect of Glutathione Depletion," <i>Radiation Res.</i> 124:208-215, Academic Press, Inc., United States (1990)	
	NPL68	LIEDTKE, W., <i>et al.</i> , "Effective Treatment of Models of Multiple Sclerosis by Matrix Metalloproteinase Inhibitors," <i>Ann. Neurol.</i> 44(1):35-46, The American Neurological Association, United States (1998)	
	NPL69	LINK, J., <i>et al.</i> , "Organ-specific autoantigens induce interferon- γ and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis," <i>Neurology</i> 44:728-734, The American Academy of Neurology, United States (1994)	
	NPL70	LINK, J., <i>et al.</i> , "Organ-specific Autoantigens Induce Transforming Growth Factor- β mRNA Expression in Mononuclear Cells in Multiple Sclerosis and Myasthenia Gravis," <i>Annals Neurol.</i> 35:197-203, The American Neurological Association, United States (1994)	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
Sheet	8	of	30
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL71	LINK, J., <i>et al.</i> , "Optic neuritis is associated with myelin basic protein and proteolipid protein reactive cells producing interferon- γ , interleukin-4 and transforming growth factor- β ," <i>J. Neuroimmunol.</i> 49:9-18, Elsevier Science B.V., Netherlands (1994)	
	NPL72	LINK, J., <i>et al.</i> , "Increased Transforming Growth Factor- β , Interleukin-4, and Interferon- γ in Multiple Sclerosis," <i>Ann. Neurol.</i> 36(3):379-386, The American Neurological Association, United States (1994)	
	NPL73	LINK, H., "The cytokine storm in multiple sclerosis," <i>Mult. Scler.</i> 4:12-15, Stockton Press, England (1998)	
	NPL74	LINKER, R.A., <i>et al.</i> , "Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies," <i>Expert Rev. Neurother.</i> 8(11):1683-1690, Expert Reviews Ltd., England (2008)	
	NPL75	LOBELL, A., <i>et al.</i> , "Suppressive DNA Vaccination in Myelin Oligodendrocyte Glycoprotein Peptide-Induced Experimental Autoimmune Encephalomyelitis Involves a T1-Biased Immune Response," <i>J. Immunol.</i> 170:1806-1813, The American Association of Immunologists, Inc., United States (2003)	
	NPL76	LOBELL, A., <i>et al.</i> , "Vaccination with DNA Encoding an Immunodominant Myelin Basic Protein Peptide Targeted to Fc of Immunoglobulin G Suppresses Experimental Autoimmune Encephalomyelitis," <i>J. Exp. Med.</i> 187(9):1543-1548, The Rockefeller University Press, United States (1998)	
	NPL77	LOPEZ, E., <i>et al.</i> , "Interferon γ , IL2, IL4, IL10 and TNF α Secretions in Multiple Sclerosis Patients Treated with an Anti-CD4 Monoclonal Antibody," <i>Autoimmunity</i> 29:87-92, OPA (Overseas Publishers Association) N.V., England (1999)	
	NPL78	LORENTZEN, J.C., <i>et al.</i> , "Genetic analysis of inflammation, cytokine mRNA expression and disease course of relapsing experimental autoimmune encephalomyelitis in DA rats," <i>J. Neuroimmunol.</i> 80:31-37, Elsevier Science N.V., Netherlands (1997)	
	NPL79	LORENTZEN, J.C., <i>et al.</i> , "Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant," <i>J. Neuroimmunol.</i> 63:193-205, Elsevier Science B.V., Netherlands (1995)	
	NPL80	LYONS, J.-A., <i>et al.</i> , "Pathogenesis of acute passive murine encephalomyelitis II. Th1 phenotype of the inducing population is not sufficient to cause disease," <i>J. Neuroimmunol.</i> 93:26-36, Elsevier Science B.V., Netherlands (1999)	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	9	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL81	MÄÄTTÄ, J.A., <i>et al.</i> , "Neutrophils secreting tumor necrosis factor alpha infiltrate the central nervous system of BALB/c mice with experimental autoimmune encephalomyelitis," <i>J. Neuroimmunol.</i> 90:162-175, Elsevier Science B.V., Netherlands (1998)	
	NPL82	MARTIN, R., <i>et al.</i> , "T helper cell differentiation in multiple sclerosis and autoimmunity," <i>Immunol. Today</i> 19(11):495-498, Elsevier Science, England (1998)	
	NPL83	MATTNER, F., <i>et al.</i> , "Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D ₃ ," <i>Eur. J. Immunol.</i> 30:498-508, WILEY-VCH Verlag GmbH, Germany (2000)	
	NPL84	MATUSEVICIUS, D., <i>et al.</i> , "Autoantigen-induced IL-13 mRNA expression is increased in blood mononuclear cells in myasthenia gravis and multiple sclerosis," <i>Eur. J. Neurol.</i> 4:468-475, Rapid Science Publishers, England (1997)	
	NPL85	ASADULLAH, K., <i>et al.</i> , "Influence of monomethylfumarate on monocytic cytokine formation - explanation for adverse and therapeutic effects in psoriasis?" <i>Arch. Dermatol. Res.</i> 289:623-630, Springer-Verlag, Germany (1997)	
	NPL86	BACHARACH-BUHLES, M., <i>et al.</i> , "The Effect of Fumaric Acid Esters and Dithranol on Acanthosis and Hyperproliferation in Psoriasis Vulgaris," <i>Acta Derm. Venereol. (Stockh)</i> 76:190-193, Scandinavian University Press, Sweden (1996)	
	NPL87	BALASHOV, K.E., <i>et al.</i> , "Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4 ⁺ T cells via CD40 ligand," <i>Proc. Natl. Acad. Sci. USA</i> 94:599-603, The National Academy of Sciences of the United States of America, United States (1997)	
	NPL88	BARCIA, C., <i>et al.</i> , "Parkinson's Disease and Inflammatory Changes," <i>Neurotox. Res.</i> 5(6):411-418, FP Graham Publishing Co., United States (2003)	
	NPL89	BREUER, K., <i>et al.</i> , "Therapy of noninfectious granulomatous skin diseases with fumaric acid esters," <i>Br. J. Dermatol.</i> 152:1290-1295, British Association of Dermatologists, England (2005)	
	NPL90	EBERLEIN-KÖNIG, B., <i>et al.</i> , "Disseminated Granuloma Annulare - Treatment with Fumaric Acid Esters," <i>Dermatology</i> 210:223-226, S. Karger AG, Switzerland (2005)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
Sheet	10	of	30	Attorney Docket Number	2159.3210002/JMC/MRG/U-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL91	LINK, H., <i>et al.</i> , "Virus-reactive and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis," <i>J. Neuroimmunol.</i> 38:63-74, Elsevier Science Publishers B.V., Netherlands (1992)	
	NPL92	LITJENS, N.H.R., <i>et al.</i> , "Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses," <i>Eur. J. Immunol.</i> 34:565-575, WILEY-VCH Verlag GmbH & Co. KGaA, Germany (2004)	
	NPL93	LITJENS, N.H.R., <i>et al.</i> , "Pharmacokinetics of oral fumarates in healthy subjects," <i>Br. J. Clin. Pharmacol.</i> 58(4):429-432, Blackwell Publishing Ltd, England (2004)	
	NPL94	LOBELL, A., <i>et al.</i> , "Presence of CpG DNA and the Local Cytokine Milieu Determine the Efficacy of Suppressive DNA Vaccination in Experimental Autoimmune Encephalomyelitis," <i>J. Immunol.</i> 163:4754-4762, The American Association of Immunologists, United States (1999)	
	NPL95	LOEWE, R., <i>et al.</i> , "Dimethylfumarate Inhibits TNF-Induced Nuclear Entry of NF- κ B/p65 in Human Endothelial Cells," <i>J. Immunol.</i> 168:4781-4787, The American Association of Immunologists, United States (2002)	
	NPL96	LUFT, R., "The development of mitochondrial medicine," <i>Proc. Natl. Acad. Sci. USA</i> 91:8731-8738, National Academy of Sciences, United States (1994)	
	NPL97	MAYNE, M., <i>et al.</i> , "Antisense Oligodeoxynucleotide Inhibition of Tumor Necrosis Factor- α Expression Is Neuroprotective After Intracerebral Hemorrhage," <i>Stroke</i> 32:240-248, American Heart Association, Inc., United States (2001)	
	NPL98	MCGEER, P.L., <i>et al.</i> , "Expression of the histocompatibility glycoprotein HLA-DR in neurological disease," <i>Acta Neuropathol.</i> 76:550-557, Springer-Verlag, Germany (1988)	
	NPL99	MUHALLAB, S., <i>et al.</i> , "Intra-CNS activation by antigen-specific T lymphocytes in experimental autoimmune encephalomyelitis," <i>J. Neuroimmunol.</i> 113:202-211, Elsevier Science B.V., Netherlands (2001)	
	NPL100	MUSIEK, E.S., <i>et al.</i> , "Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration," <i>J. Neurochem.</i> 97:1301-1313, International Society for Neurochemistry, England (2006)	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	11	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL101	MUSTAFA, M.I., <i>et al.</i> , "T cell immunity and interferon- γ secretion during experimental allergic encephalomyelitis in Lewis rats," <i>J. Neuroimmunol.</i> 31:165-177, Elsevier Science Publishers B.V., Netherlands (1991)	
	NPL102	MUSTAFA, M., <i>et al.</i> , "Immunopharmacologic Modulation of Experimental Allergic Encephalomyelitis: Low-Dose Cyclosporin-A Treatment Causes Disease Relapse and Increased Systemic T and B Cell-Mediated Myelin-Directed Autoimmunity," <i>Scand. J. Immunol.</i> 38:499-507, Blackwell Scientific Publications, England (1993)	
	NPL103	MUSTAFA, M., <i>et al.</i> , "The major histocompatibility complex influences myelin basic protein 63-88-induced T cell cytokine profile and experimental autoimmune encephalomyelitis," <i>Eur. J. Immunol.</i> 23:3089-3095, VCH Verlagsgesellschaft mbH, Germany (1993)	
	NPL104	MUSTAFA, M., <i>et al.</i> , "Protective Influences on Experimental Autoimmune Encephalomyelitis by MHC Class I and Class II Alleles," <i>J. Immunol.</i> 153:3337-3344, The American Association of Immunologists, United States (1994)	
	NPL105	NAVIKAS, V., <i>et al.</i> , "Increased mRNA Expression of IL-10 in Mononuclear Cells in Multiple Sclerosis and Optic Neuritis," <i>Scand. J. Immunol.</i> 41:171-178, Blackwell Scientific Publications, England (1995)	
	NPL106	NAVIKAS, V., <i>et al.</i> , "Augmented expression of tumour necrosis factor- α and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis," <i>Brain</i> 119:213-223, Oxford University Press, England (1996)	
	NPL107	NIBBERING, P.H., <i>et al.</i> , "Effects of Monomethylfumarate on Human Granulocytes," <i>J. Invest. Dermatol.</i> 101:37-42, The Society for Investigative Dermatology, Inc., United States (1993)	
	NPL108	NIBBERING, P.H., <i>et al.</i> , "Intracellular signalling by binding sites for the antipsoriatic agent monomethylfumarate on human granulocytes," <i>Br. J. Dermatol.</i> 137:65-75, British Association of Dermatologists, England (1997)	
	NPL109	NIEBOER, C., <i>et al.</i> , "Systemic therapy with fumaric acid derivates: New possibilities in the treatment of psoriasis," <i>J. Am. Acad. Dermatol.</i> 20:601-608, Mosby, United States (1989)	
	NPL110	OCKENFELS, H.M., <i>et al.</i> , "The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network," <i>Br. J. Dermatol.</i> 139:390-395, British Association of Dermatologists, England (1998)	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	12	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL111	OLSSON, T., <i>et al.</i> , "Autoreactive T Lymphocytes in Multiple Sclerosis Determined by Antigen-induced Secretion of Interferon- γ ," <i>J. Clin. Invest.</i> 86:981-985, The American Society for Clinical Investigation, Inc., United States (1990)	
	NPL112	OLSSON, T., "Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-gamma," <i>J. Neuroimmunol.</i> 40:211-218, Elsevier Science Publishers B.V., Netherlands (1992)	
	NPL113	OLSSON, T., <i>et al.</i> , "Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis," <i>Eur. J. Immunol.</i> 22:1083-1087, VCH Verlagsgesellschaft mbH, Germany (1992)	
	NPL114	OLSSON, T., "Cerebrospinal Fluid," <i>Ann. Neurol.</i> 36:S100-S102, American Neurological Association, United States (1994)	
	NPL115	OLSSON, T., "Role of cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis," <i>Eur. J. Neurol.</i> 1:7-19, Rapid Communications of Oxford Ltd., England (1994)	
	NPL116	OLSSON, T., "Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis," <i>Neurology</i> 45(Suppl 6):S11-S15, Lipincott Williams & Wilkins, United States (1995)	
	NPL117	OLSSON, T., <i>et al.</i> , "Genetics of rat neuroinflammation," <i>J. Neuroimmunol.</i> 107:191-200, Elsevier Science B.V., Netherlands (2000)	
	NPL118	OLSSON, T., <i>et al.</i> , "Depletion of V β 5.2/5.3 T cells with a humanized antibody in patients with multiple sclerosis," <i>Eur. J. Neurol.</i> 9:153-164, European Federation of Neurological Societies, England (2002)	
	NPL119	OLSSON, T., <i>et al.</i> , "Harm or heal - divergent effects of autoimmune neuroinflammation?" <i>TRENDS in Immunol.</i> 24(1):5-6, Elsevier Science Ltd., England (2003)	
	NPL120	PANITCH, H.S., <i>et al.</i> , "Exacerbations Of Multiple Sclerosis In Patients Treated With Gamma Interferon," <i>Lancet</i> 329:893-895, Lancet Publishing Group, England (1987)	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	13	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL121	PEREIRA, M.A., <i>et al.</i> , "Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents," <i>Carcinogenesis</i> 15(5):1049-1054, Oxford University Press, England (1994)	
	NPL122	PETTE, M., <i>et al.</i> , "Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones," <i>J. Neuroimmunol.</i> 98:147-156, Elsevier Science B.V., Netherlands (1999)	
	NPL123	PROCHASKA, H.J., <i>et al.</i> , "Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication," <i>Proc. Natl. Acad. Sci. USA</i> 90:3953-3957, National Academy of Sciences, United States	
	NPL124	PROCHASKA, H.J., <i>et al.</i> , "Elevation of Glutathione Levels by Phase II Enzyme Inducers: Lack of Inhibition of Human Immunodeficiency Virus Type 1 Replication in Chronically Infected Monocytoid Cells," <i>Mol. Pharmacol.</i> 45:916-921, The American Society for Pharmacology and Experimental Therapeutics, United States (1994)	
	NPL125	RAO, C.V., <i>et al.</i> , "Chemoprevention of Azoxymethane-Induced Colon Cancer by Ascorbylpalmitate, Carbenoxolone, Dimethylfumarate and <i>p</i> -Methoxyphenol in Male F344 Rats," <i>Anticancer Res.</i> 15:1199-1204, Anticancer Research, Greece (1995)	
	NPL126	RAO, K.S. and MISHRA, S.H., "Antihepatotoxic activity of monomethyl fumarate isolated from <i>Fumaria indica</i> ," <i>J. Ethnopharmacol.</i> 60:207-213, Elsevier Science Ireland Ltd., Ireland (1998)	
	NPL127	RISTORI, G., <i>et al.</i> , "T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis," <i>J. Neuroimmunol.</i> 99:91-96, Elsevier Science B.V., Netherlands (1999)	
	NPL128	ROBINSON, W.H., <i>et al.</i> , "Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis," <i>Nat. Biotechnol.</i> 21(9):1033-1039, Nature Publishing Group, United States (2003)	
	NPL129	ROHOWSKY-KOCHAN, C., <i>et al.</i> , "Impaired interleukin-12 production in multiple sclerosis patients," <i>Mult. Scler.</i> 5:327-334, Stockton Press, England (1999)	
	NPL130	ROHOWSKY-KOCHAN, C., <i>et al.</i> , "Cytokine secretion profile of myelin basic protein-specific T cells in multiple sclerosis," <i>Mult. Scler.</i> 6:69-77, Macmillan Publishers Ltd., England (2000)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	14	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL131	ROMAGNANI, S., "The Th1/Th2 paradigm," <i>Immunol. Today</i> 18(6):263-266, Elsevier Science Ltd., England (1997)	
	NPL132	ROOK, G.A.W., <i>et al.</i> , "Bacterial vaccines for the treatment of multiple sclerosis and other autoimmune diseases," <i>Immunol. Today</i> 21(10):503-508, Elsevier Science Ltd., England (2000)	
	NPL133	SAMOILOVA, E.B., <i>et al.</i> , "Experimental Autoimmune Encephalomyelitis in Intercellular Adhesion Molecule-1-Deficient Mice," <i>Cell. Immunol.</i> 190:83-89, Academic Press, United States (1998)	
	NPL134	SEBÖK, B., <i>et al.</i> , "Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures," <i>Eur. J. Pharmacol.</i> 270:79-87, Elsevier Science B.V., Netherlands (1994)	
	NPL135	SEBÖK, B., <i>et al.</i> , "Effect of Fumaric Acid, Its Dimethylester, and Topical Antipsoriatic Drugs on Epidermal Differentiation in the Mouse Tail Model," <i>Skin Pharmacol.</i> 9:99-103, S. Karger AG, Switzerland (1996)	
	NPL136	SINGH, V.K., <i>et al.</i> , "The Paradigm of Th1 and Th2 Cytokines. Its Relevance to Autoimmunity and Allergy," <i>Immunol. Res.</i> 20:147-161, Humana Press Inc., United States (1999)	
	NPL137	SINIGAGLIA, F., <i>et al.</i> , "Type I interferons and the Th1/Th2 paradigm," <i>Dev. Comp. Immunol.</i> 23:657-663, Elsevier Science Ltd., United States (1999)	
	NPL138	SMELTZ, R.B. and SWANBORG, R.H., "Concordance and Contradiction Concerning Cytokines and Chemokines in Experimental Demyelinating Disease," <i>J. Neurosci. Res.</i> 51:147-153, Wiley-Liss, Inc., United States (1998)	
	NPL139	SÖDERSTRÖM, M., <i>et al.</i> , "T Cells Recognizing Multiple Peptides of Myelin Basic Protein are Found in Blood and Enriched in Cerebrospinal Fluid in Optic Neuritis and Multiple Sclerosis," <i>Scand. J. Immunol.</i> 37:355-368, Blackwell Scientific Publications, England (1993)	
	NPL140	SPENCER, S.R., <i>et al.</i> , "Induction of Glutathione Transferases and NAD(P)H:Quinone Reductase by Fumaric Acid Derivatives in Rodent Cells and Tissues," <i>Cancer Res.</i> 50:7871-7875, American Association for Cancer Research, United States (1990)	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	15	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL141	SU, J.Y.C., <i>et al.</i> , "Reduction of H ₂ O ₂ -evoked, intracellular calcium increases in the rat N18-RE-105 neuronal cell line by pretreatment with an electrophilic antioxidant inducer," <i>Neurosci. Lett.</i> 273:109-112, Elsevier Science Ireland Ltd., Ireland (1999)	
	NPL142	SUN, J.-B., <i>et al.</i> , "Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit," <i>Proc. Natl. Acad. Sci. USA</i> 93:7196-7201, National Academy of Sciences, United States (1996)	
	NPL143	THIO, H.B., <i>et al.</i> , "Fumaric acid derivatives evoke a transient increase in intracellular free calcium concentration and inhibit the proliferation of human keratinocytes," <i>Brit. J. Dermatol.</i> 131:856-861, Blackwell Scientific Publications, England (1994)	
	NPL144	VENTEN, I., <i>et al.</i> , "Treatment of Therapy-Resistant Alopecia Areata With Fumaric Acid Esters," <i>Eur. J. Med. Res.</i> 11:300-305, I. Holzapfel Publishers, Germany (July 2006)	
	NPL145	WALLSTRÖM, E., <i>et al.</i> , "Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis," <i>J. Neurol. Sci.</i> 137:89-96, Elsevier Science B.V., Netherlands (1996)	
	NPL146	WALLSTRÖM, E., <i>et al.</i> , "Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis," <i>Eur. J. Immunol.</i> 28:3329-3335, Wiley-VCH Verlag GmbH, Germany (1998)	
	NPL147	WANG, W.Z., <i>et al.</i> , "Myelin antigen reactive T cells in cerebrovascular diseases," <i>Clin. Exp. Immunol.</i> 88:157-162, Blackwell Scientific Publications, England (1992)	
	NPL148	WEISSERT, R., <i>et al.</i> , "Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen," <i>Proc. Natl. Acad. Sci. USA</i> 97(4):1689-1694, National Academy of Sciences, United States (2000)	
	NPL149	WRIGHT, R., "Autoimmune disease of the gastro-intestinal tract," <i>Postgrad. med. J.</i> 44:765-768, BMJ Publishing Group, England (1968)	
	NPL150	ZHU, J., <i>et al.</i> , "Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome," <i>J. Neuroimmunol.</i> 84:40-52, Elsevier Science B.V., Netherlands (1998)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	16	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL151	ZIPP, F., "No Evidence for Generation of Th-2-like MBP-Specific T-Cell Lines by Blockade of the Costimulatory Molecule B7-1," <i>Scand. J. Immunol.</i> 52:510-514, Blackwell Science Ltd., England (2000)	
	NPL152	ALEXANDER, A. and WONG, S., "Graft Versus Host Disease - Pathophysiology & Management," <i>Jacksonville Medicine: Bone Marrow Transplantation</i> 51(11):1-7, Duval County Medical Society Foundation for the Duval, Clay, Nassau, St. Johns & Putnam Medical Societies, United States (2000)	
	NPL153	ANDERSON, J., <i>et al.</i> , "Aetiology of Multiple Sclerosis," <i>Br. Med. J</i> 1(5433):466-467, British Medical Association, England (1965)	
	NPL154	BROCHET, B., "[Non-specific immunosuppression and multiple sclerosis]," <i>Rev. Neurol. (Paris)</i> 154(8-9):629-634, Masson, France (1998) (Abstract Only)	Abs.
	NPL155	CALABRESE, V., <i>et al.</i> , "Acetylcarnitine Induces Heme Oxygenase in Rat Astrocytes and Protects Against Oxidative Stress: Involvement of the Transcription Factor Nrf2," <i>J. Neurosci. Res.</i> 79:509-521, Wiley-Liss, Inc., United States (2005)	
	NPL156	CHEN, X.-L. and KUNSCH, C., "Induction of Cytoprotective Genes Through Nrf2/Antioxidant Response Element Pathway: A New Therapeutic Approach for the Treatment of Inflammatory Diseases," <i>Curr. Pharm. Des.</i> 10:879-891, Bentham Science Publishers Ltd., Netherlands (2004)	
	NPL157	CORAS, B., <i>et al.</i> , "Fumaric acid esters therapy: a new treatment modality in pityriasis rubra pilaris?" <i>Br. J. Dermatol.</i> 152:388-389, British Association of Dermatologists, England (2005)	
	NPL158	FOX, R.J., "BG00012 - A Novel Oral Therapy in Development for the Treatment of Multiple Sclerosis," <i>European Neurological Review</i> 3(1):99-103, Touch Briefings, England (2008)	
	NPL159	GAMBICHLER, T., <i>et al.</i> , "Clearance of Necrobiosis lipoidica with Fumaric Acid Esters," <i>Dermatology</i> 207(4):422-424, S. Karger AG, Switzerland (2003)	
	NPL160	GAO, L., <i>et al.</i> , "Novel N-3 Fatty Acid Oxidation Products Activate Nrf2 By Destabilizing The Association Between Keap1 and Cullin3," <i>J. Biol. Chem.</i> M607622200, 18 pages, The American Society for Biochemistry and Molecular Biology, Inc., United States (November 2006)	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
Sheet	17	of	30
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL161	GILGUN-SHERKI, Y., <i>et al.</i> , "The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy," <i>J. Neurol.</i> 251:261-268, Springer-Verlag, Germany (2004)	
	NPL162	GRAVES, M.C., <i>et al.</i> , "Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells," <i>Amyotroph. Lateral Scler. Other Motor Neuron Disord.</i> 5:213-219, Martin Dunitz, England (2004)	
	NPL163	GUTZMER, R., <i>et al.</i> , "Erfolgreiche Therapie einer Haut- und Lungensarkoidose mit Fumarsäureestern," <i>Hautarzt</i> 55:553-557, Springer-Verlag, Germany (2004)	
	NPL164	GUTZMER, R., <i>et al.</i> , "[Successful treatment of skin and lung sarcoidosis with fumaric acid ester].," <i>Hautarzt</i> 55:553-557, Springer-Verlag, Germany (2004) (Abstract Only)	Abs.
	NPL165	HAGEDORN, M., <i>et al.</i> , "Therapie der rezidivierenden benignen Aphthosis mit Fumarsäureestern," <i>Akt. Dermatol.</i> 31:383-387, Georg Thieme Verlag KG, Germany (2005) (Abstract Only in English)	Abs.
	NPL166	KENSLER, T.W., <i>et al.</i> , "Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway," <i>Annu. Rev. Pharmacol. Toxicol.</i> 47:6.1-6.28, Annual Reviews, United States (2007; Epub August 2006)	
	NPL167	KREUTER, A., <i>et al.</i> , "Treatment of disseminated granuloma annulare with fumaric acid esters," <i>BMC Dermatol.</i> 2(5):1-4, BioMed Central Ltd., England (2002)	
	NPL168	KREUTER, A., <i>et al.</i> , "Fumaric acid esters in necrobiosis lipoidica: results of a prospective noncontrolled study," <i>Br. J. Dermatol.</i> 153:802-807, British Association of Dermatologists, England (2005)	
	NPL169	KWAK, M.-K., <i>et al.</i> , "Enhanced Expression of the Transcription Factor Nrf2 by Cancer Chemopreventive Agents: Role of Antioxidant Response Element-Like Sequences in the <i>nrf2</i> Promoter," <i>Mol. Cell Biol.</i> 22(9):2883-2892, American Society for Microbiology, United States (2002)	
	NPL170	KWAK, M.-K., <i>et al.</i> , "Modulation of Gene Expression by Cancer Chemopreventive Dithiolethiones through the Keap1-Nrf2 Pathway," <i>J. Biol. Chem.</i> 278(10):8135-8145, The American Society for Biochemistry and Molecular Biology, Inc., United States (2003)	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	18	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T 2
	NPL171	LAHTI, A., <i>et al.</i> , "Acetylsalicylic acid inhibits non-immunologic contact urticaria," <i>Contact Dermatitis</i> 16:133-135, Munksgaard International Publishers Ltd., Denmark (1987)	
	NPL172	LEE, J.-M., <i>et al.</i> , "Identification of the NF-E2-related Factor-2-dependent Genes Conferring Protection against Oxidative Stress in Primary Cortical Astrocytes Using Oligonucleotide Microarray Analysis," <i>J. Biol. Chem.</i> 278(14):12029-12038, The American Society for Biochemistry and Molecular Biology, Inc., United States (2003)	
	NPL173	LEHMANN, J.C.U., <i>et al.</i> , "Dimethylfumarate Induces Immunosuppression via Glutathione Depletion and Subsequent Induction of Heme Oxygenase 1," <i>J. Invest. Dermatol.</i> 127:835-845, The Society for Investigative Dermatology, United States (Epub January 18, 2007)	
	NPL174	LIANG, Q., <i>et al.</i> , "Noninvasive, Repetitive, Quantitative Measurement of Gene Expression from a Bicistronic Message by Positron Emission Tomography, Following Gene Transfer with Adenovirus," <i>Mol. Ther.</i> 6(1):73-82, The American Society of Gene Therapy, United States (2002)	
	NPL175	LUKER, G.D., <i>et al.</i> , "Noninvasive Bioluminescence Imaging of Herpes Simplex Virus Type 1 Infection and Therapy in Living Mice," <i>J. Virol.</i> 76(23):12149-12161, American Society for Microbiology, United States (2002)	
	NPL176	MA, Q., <i>et al.</i> , "Multiorgan Autoimmune Inflammation, Enhanced Lymphoproliferation, and Impaired Homeostasis of Reactive Oxygen Species in Mice Lacking the Antioxidant-Activated Transcription Factor <i>Nrf2</i> ," <i>Am. J. Pathol.</i> 168(6):1960-1974, American Society for Investigative Pathology, United States (June 2006)	
	NPL177	MATTSON, M.P. and CHENG, A., "Neurohormetic phytochemicals: low-dose toxins that induce adaptive neuronal stress responses," <i>TRENDS in Neurosciences</i> 29(11):632-639, Elsevier Ltd., England (September 2006)	
	NPL178	NGUYEN, T., <i>et al.</i> , "Nrf2 Controls Constitutive and Inducible Expression of ARE-driven Genes through a Dynamic Pathway Involving Nucleocytoplasmic Shuttling by Keap1," <i>J. Biol. Chem.</i> 280(37):32485-32492, The American Society for Biochemistry and Molecular Biology, Inc., United States (2005)	
	NPL179	NIEBOER, C., <i>et al.</i> , "Fumaric Acid Therapy in Psoriasis: A Double-Blind Comparison between Fumaric Acid Compound Therapy and Monotherapy with Dimethylfumaric Acid Ester," <i>Dermatologica</i> 181:33-37, Karger AG, Switzerland (1990)	
	NPL180	NOWACK, U., <i>et al.</i> , "Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters," <i>BMC Dermatol.</i> 2(15):1-5, BioMed Central Ltd., England (2002)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	19	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL181	O'GARRA, A., <i>et al.</i> , "CD4 ⁺ T-cell subsets in autoimmunity," <i>Curr. Opin. Immunol.</i> 9:872-883, Current Biology Ltd., England (1997)	
	NPL182	OLSSON, T., <i>et al.</i> , "Chapter 22: MHC and Non-MHC Genetics of Experimental Autoimmune Encephalomyelitis," in <i>From Basic Immunology to Immune-Mediated Demyelination</i> , Martino, G. and Adorini, L., eds., p. 246-264, Springer-Verlag, Italy (1999)	
	NPL183	OLSSON, T., "Critical Influences of the Cytokine Orchestration on the Outcome of Myelin Antigen-Specific T-Cell Autoimmunity in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis," <i>Immunol. Rev.</i> 144:245-268, Munksgaard, Denmark (1995)	
	NPL184	PASHENKOV, M., <i>et al.</i> , "Recruitment of dendritic cells to the cerebrospinal fluid in bacterial neuroinfections," <i>J. Neuroimmunol.</i> 122:106-116, Elsevier Science B.V., Netherlands (2002)	
	NPL185	PERMANA, P.A., <i>et al.</i> , "Macrophage-secreted factors induce adipocyte inflammation and insulin resistance," <i>Biochem. Biophys. Res. Commun.</i> 341:507-514, Elsevier Inc., United States (Epub January 2006)	
	NPL186	PETTE, M., <i>et al.</i> , "In vitro modulation of human, autoreactive MBP-specific CD4 + T-cell clones by cyclosporin A," <i>J. Neuroimmunol.</i> 76:91-99, Elsevier Science B.V., Netherlands (1997)	
	NPL187	ROODNAT, J.I., <i>et al.</i> , "Akute Niereninsuffizienz bei der Behandlung der Psoriasis mit Fumasäure-Estern," <i>Schweiz. med. Wschr.</i> 119:826-830, Basel, B. Schwabe & Co., Switzerland (1989) (Abstract Only in English)	Abs.
	NPL188	RUDGE, P., "Cyclosporine and multiple sclerosis: The cons," <i>Neurology</i> 38(7)(Suppl 2):29-30, Lippincott Williams & Wilkins, United States (1988)	
	NPL189	RUULS, S.R., <i>et al.</i> , "The Length of Treatment Determines Whether IFN- β Prevents or Aggravates Experimental Autoimmune Encephalomyelitis in Lewis Rats," <i>J. Immunol.</i> 157:5721-5731, The American Association of Immunologists, United States (1996)	
	NPL190	SATOH, T., <i>et al.</i> , "Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic phase II inducers," <i>Proc. Natl. Acad. Sci. USA</i> 103(3):768-773, The National Academy of Sciences of the USA, United States (January 2006)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO			Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	<i>To be assigned</i>
			Filing Date	Herewith
			First Named Inventor	Matvey E. LUKASHEV
			Art Unit	<i>To be assigned</i>
			Examiner Name	<i>To be assigned</i>
			Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	20	of	30	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL191	SCHILLING, F. and SCHOPF, R.E., "Adultes Debré-de Toni-Fanconi-Syndrom mit Osteomalazie, erworben durch Langzeittherapie einer Psoriasis mit Fumarsäureester - zugleich ein Beitrag zur malazischen Osteoarthropathie," <i>Akt. Rheumatol.</i> 24(6):174-179, Georg Thieme Verlag, Germany (1999) (Abstract Only in English)	Abs.
	NPL192	SCHILLING, S., <i>et al.</i> , "Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration," <i>Clin. Exp. Immunol.</i> 145:101-107, British Society for Immunology, England (2006)	
	NPL193	SCHWINGHAMMER, T.L. and BLOOM, E.J., "Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation," <i>Clinical Pharm.</i> 12:736-761, American Society of Hospital Pharmacists, Inc., United States (1993)	
	NPL194	SHIH, A.Y., <i>et al.</i> , "A Small-Molecule-Inducible Nrf2-Mediated Antioxidant Response Provides Effective Prophylaxis against Cerebral Ischemia <i>In Vivo</i> ," <i>J. Neurosci.</i> 25(44):10321-10335, Society for Neuroscience, United States (2005)	
	NPL195	SUMMERS, S.A., "Ceramides in insulin resistance and lipotoxicity," <i>Prog. Lipid Res.</i> 45:42-72, Elsevier Ltd., England (January 2006; Epub December 2005)	
	NPL196	THIMMULAPPA, R.K., <i>et al.</i> , "Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis," <i>J. Clin. Invest.</i> 116(4):984-995, American Society for Clinical Investigation, United States (April 2006)	
	NPL197	VAN HORSSSEN, J., <i>et al.</i> , "NAD(P)H:quinone oxidoreductase 1 expression in multiple sclerosis lesions," <i>Free Radic. Biol. Med.</i> 41:311-317, Elsevier Inc., United States (Epub April 2006)	
	NPL198	VAN LOENEN, A.C., <i>et al.</i> , "Fumaarzuurtherapie: van fictie tot werkelijkheid?" <i>Pharm. Weekbl.</i> 124:894-900, D B Centens Witgeversmij, Netherlands (1989) (Abstract Only in English)	Abs.
	NPL199	VANDERMEEREN, M., <i>et al.</i> , "Dimethylfumarate Is an Inhibitor of Cytokine-Induced E-Selection, VCAM-1, and ICAM-1 Expression in Human Endothelial Cells," <i>Biochem. Biophys. Res. Comm.</i> 234:19-23, Academic Press, United States (1997)	
	NPL200	VANDERMEEREN, M., <i>et al.</i> , "Dimethylfumarate is an Inhibitor of Cytokine-Induced Nuclear Translocation of NF- κ B1, But Not RelA in Normal Human Dermal Fibroblast Cells," <i>J. Inves. Dermatol.</i> 116:124-130, The Society for Investigative Dermatology, Inc., United States (2001)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	21	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL201	WAKABAYASHI, N., <i>et al.</i> , "Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation," <i>Nat. Genet.</i> 35(3):238-245, Nature Publishing Group, United States (2003)	
	NPL202	WANSCHER, B. and SØRENSEN, P.S., "Nye behandlingsmuligheder for dissemineret sklerose?" <i>Ugeskr Læger</i> 156(43):6353-6358, Den Alm Danske Laegerforening, Denmark (1994) (Abstract Only in English)	Abs.
	NPL203	WERDENBERG, D., <i>et al.</i> , "Presystemic Metabolism and Intestinal Absorption of Antipsoriatic Fumaric Acid Esters," <i>Biopharm. Drug Dispos.</i> 24(6):259-273, John Wiley & Sons, Ltd., England (2003)	
	NPL204	WERDENBERG, D., <i>Stability, Permeability and Pharmacokinetics of Perorally Administered Fumarates</i> , Doctoral Dissertation submitted to the Swiss Federal Institute of Technology Zurich, pp. 86, 87, 90, 125 (2003)	
	NPL205	ZHU, K. and MROWIETZ, U., "Inhibition of Dendritic Cell Differentiation by Fumaric Acid Esters," <i>J. Invest. Dermatol.</i> 116:203-208, The Society for Investigative Dermatology, Inc., United States (2001)	
	NPL206	The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, "TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study," <i>Neurol.</i> 53:457-465, American Academy of Neurology, United States (1999)	
	NPL207	"Oral Compound BG-12 Achieves Primary Endpoint in Phase II Study of Relapsing-Remitting Multiple Sclerosis; Treatment with BG-12 Led to Statistically Significant Reductions in MRI Measures," Biogen Idec, accessed at http://phx.corporate-ir.net/staging/phoenix.zhtml?c=148682&p=irol-newsArticle_print&ID=861749&highlight , published online May 30, 2006, 2 pages	
	NPL208	"Phase II Study of Oral Compound BG-12 Meets Primary Endpoint in Multiple Sclerosis," Biogen Idec, accessed at http://phx.corporate-ir.net/staging/phoenix.zhtml?c=148682&p=irol-newsArticle_print&ID=801882&highlight , published online January 9, 2006, 1 page	
	NPL209	"Polyarthritis," Wikipedia.org, accessed at www.en.wikipedia.org/wiki/Polyarthritis , accessed on September 3, 2008, 4 pages	
	NPL210	<i>Immunomodulation durch Fumaderm. Das richtungsweisende Konzept</i> , Charite-Berlin Hautklinik Symposium, November 1-3, 1996, p. 1-27	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
Sheet	22	of	30
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL211	Partial English language translation, 4 pages, of <i>Immunomodulation durch Fumaderm. Das richtungsweisende Konzept</i> , Charite-Berlin Hautklinik Symposium, November 1-3, 1996, p. 1-27	
	NPL212	ANDO, D.G., <i>et al.</i> , "Encephalitogenic T Cells in the B10.PL Model of Experimental Allergic Encephalomyelitis (EAE) Are of the Th-1 Lymphokine Subtype," <i>Cell. Immunol.</i> 124:132-143, Academic Press, Inc., United States (1989)	
	NPL213	BAKER, D., <i>et al.</i> , "Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice," <i>J. Neuroimmunol.</i> 28(3):261-270, Elsevier Science Publishers B.V. (Biomedical Division), Netherlands, (1990)	
	NPL214	BAXTER, A.G., <i>et al.</i> , "High And Low Diabetes Incidence Nonobese Diabetic (NOD) Mice: Origins And Characterisation," <i>Autoimmunity</i> 9:61-67, Harwood Academic Publishers GmbH, England (1991)	
	NPL215	BAYARD, W., <i>et al.</i> , "Perorale Langzeitbehandlung der Psoriasis mit Fumarsäurederivaten" <i>Hautarzt</i> 38:279-285, Springer-Verlag, Germany (1987) (Abstract Only in English)	Abs.
	NPL216	BEN-NUN, A., <i>et al.</i> , "The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis," <i>Eur. J. Immunol.</i> 11:195-199, Verlag Chemie, GmbH, Germany (1981)	
	NPL217	BUTTER, C., <i>et al.</i> , "Mononuclear cell trafficking and plasma protein extravasation into the CNS during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice," <i>J. Neurol. Sci.</i> 104:9-12, Elsevier Science Publishers B.V., Netherlands (1991)	
	NPL218	DINKOVA-KOSTOVA, A.T., <i>et al.</i> , "Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups," <i>Proc. Natl. Acad. Sci. USA</i> 98(6):3404-3409, National Academy of Sciences, United States (2001)	
	NPL219	<i>Encyclopedia of Molecular Biology and Molecular Medicine</i> , Meyers, R.A., ed., p. 343, VCH Verlagsgesellschaft mbH, Germany (1996)	
	NPL220	ERCOLINI, A.M. and MILLER, S.D., "Mechanisms of Immunopathology in Murine Models of Central Nervous System Demyelinating Disease," <i>J. Immunol.</i> 176(6):3293-3298, The American Association of Immunologists, Inc., United States (March 2006)	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	23	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL221	EUGSTER, H.-P., <i>et al.</i> , "Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1," <i>Eur. J. Immunol.</i> 29:626-632, WILEY-VCH Verlag GmbH, Germany (1999)	
	NPL222	FREIREICH, E.J., <i>et al.</i> , "Quantitative Comparison Of Toxicity Of Anticancer Agents In Mouse, Rat, Hamster, Dog, Monkey, And Man," <i>Cancer Chemother. Reports</i> 50(4):219-244, National Cancer Institute, United States (1966)	
	NPL223	FRIEDRICH, M., <i>et al.</i> , "Addition of Pentoxifylline Could Reduce the Side Effects of Fumaric Acid Esters in the Treatment of Psoriasis," <i>Acta Derm. Venereol.</i> 81:429-430, Taylor & Francis, Sweden (2001)	
	NPL224	GOLD, R., <i>et al.</i> , "Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research," <i>Brain</i> 129:1953-1971, Oxford University Press, England (August 2006)	
	NPL225	HABIG, W.H., <i>et al.</i> , "Glutathione S-Transferases: The First Enzymatic Step in Mercapturic Acid Formation," <i>J. Biol. Chem.</i> 249(22):7130-7139, The American Society for Biological Chemists, Inc., United States (1974)	
	NPL226	HARRIS, J.O., <i>et al.</i> , "Serial Gadolinium-enhanced Magnetic Resonance Imaging Scans in Patients with Early, Relapsing-Remitting Multiple Sclerosis: Implications for Clinical Trials and Natural History," <i>Ann. Neurol.</i> 29:548-555, American Neurological Association, United States (1991)	
	NPL227	HARTUNG, H.-P., <i>et al.</i> , "The Role Of Macrophages And Eicosanoids In The Pathogenesis Of Experimental Allergic Neuritis," <i>Brain</i> 111:1039-1059, Oxford University Press, England (1988)	
	NPL228	HEMMINKI, A., <i>et al.</i> , "In Vivo Molecular Chemotherapy and Noninvasive Imaging With an Infectivity-Enhanced Adenovirus," <i>J. Natl. Cancer Inst.</i> 94(10):741-749, Oxford University Press, United States (2002)	
	NPL229	Jl, H., <i>et al.</i> , "Different modes of pathogenesis in T-cell-dependent autoimmunity: clues from two TCR transgenic systems," <i>Immunol. Rev.</i> 169:139-146, Munksgaard International Publishers, Denmark (1999)	
	NPL230	KAPPOS, L., <i>et al.</i> , "Efficacy of a novel oral single-agent Fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase II study," oral presentation on May 30, 2006, at the 16th Meeting of the European Neurological Society, May 27-31, 2006, Lausanne, Switzerland	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	24	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL231	KAPPOS, L., <i>et al.</i> , "Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study," Abstract O108, Proceedings of the 16th Meeting of the European Neurological Society, May 27-31, 2006, Lausanne, Switzerland (Abstract Only)	Abs.
	NPL232	KAPPOS, L., <i>et al.</i> , "The Efficacy of BG00012 in Patients With Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses From the Phase 2b Study," poster from the 60th Annual Meeting of the American Academy of Neurology, April 12-19, 2008, Chicago, IL, United States	
	NPL233	KERMODE, A.G., <i>et al.</i> , "Breakdown Of The Blood-Brain Barrier Precedes Symptoms And Other MRI Signs Of New Lesions In Multiple Sclerosis," <i>Brain</i> 113:1477-1489, Oxford University Press, England (1990)	
	NPL234	"Klinische Studie mit Fumaderm [®] als magensaftresistente Mikrotabletten," Report, 11 pages	
	NPL235	KURODA, K. and AKAO, M., "Antitumor And Anti-Intoxication Activities Of Fumaric Acid In Cultured Cells," <i>Gann</i> 72(5):777-782, Japanese Cancer Association and the Japanese Foundation for Cancer Research, Japan (1981)	
	NPL236	Biosis Database, Accession No. PREV197662032843, English language abstract for KURODA, K., <i>et al.</i> , "Inhibitory Effect Of Capsella-Bursa-Pastoris Extract On Growth Of Ehrlich Solid Tumor In Mice," <i>Cancer Res.</i> 36(6):1900-1903, American Association for Cancer Research, United States (1976) (Abstract Only)	Abs.
	NPL237	LINKER, R.A., <i>et al.</i> , "CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation," <i>Nature Medicine</i> 8(6):620-624, Nature America Inc., United States (2002)	
	NPL238	LODIE, T.A., <i>et al.</i> , "Systematic Analysis of Reportedly Distinct Populations of Multipotent Bone Marrow-Derived Stem Cells Reveals a Lack of Distinction," <i>Tissue Eng.</i> 8(5):739-751, Mary Ann Liebert, Inc., United States (2002)	
	NPL239	MENDEL, I., <i>et al.</i> , "A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2 ^b mice: fine specificity and T cell receptor V β expression of encephalitogenic T cells," <i>Eur. J. Immunol.</i> 25:1951-1959, VCH Verlagsgesellschaft mbH, Germany (1995)	
	NPL240	<i>The Merck Manual of Diagnosis and Therapy</i> , 15 th Edition, Berkow, R. and Fletcher, A.J., eds., p. 327, Merck Sharp & Dohme Research Lab, United States (1987)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	25	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL241	NIEBOER, C., <i>et al.</i> , "Treatment of psoriasis with fumaric acid derivatives," <i>Proceedings of the 239th Meeting of the Netherlands Society for Dermatology and Venereology Amsterdam, 14 February 1987, Br. J. Dermatol. 117(6):791-92, Blackwell Scientific Publications, England (1987) (Abstract Only)</i>	Abs.
	NPL242	NIOI, P. and HAYES, J.D., "Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors," <i>Mutat. Res. 555:149-171, Elsevier B.V., Netherlands (2004)</i>	
	NPL243	OLSSON, T., "15: Future prospects of cytokines in the pathogenesis and management of multiple sclerosis," in <i>Frontiers in Multiple Sclerosis, Volume 2</i> , p. 139-150, Siva, A., <i>et al.</i> , eds., Martin Dunitz Ltd., England (1999)	
	NPL244	OLSSON, T., "Chapter 6: Cytokines in Multiple Sclerosis and Its Experimental Models," in <i>Neuroscience Intelligence Unit 5: T-Cell Autoimmunity and Multiple Sclerosis</i> , Londei, M., ed., p. 91-112, R.G. Landes Company, United States (1999)	
	NPL245	Biosis Database, Accession No. PREV199497368291, English language abstract for PEARL, J.M., <i>et al.</i> , "Fumarate-enriched blood cardioplegia results in complete functional recovery of immature myocardium," <i>Ann. Thorac. Surg. 57(6):1636-1641, Elsevier, Netherlands (1994) (Abstract Only)</i>	Abs.
	NPL246	PEETERS, A.J., <i>et al.</i> , "Fumaric Acid Therapy for Psoriatic Arthritis. A Randomized, Double-blind, Placebo-controlled Study," <i>Br. J. Rheumatol. XXXI(7):502-504, British Association for Rheumatology and Rehabilitation, England (1992)</i>	
	NPL247	PEETERS, A.J., <i>et al.</i> , "Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo-gecontroleerd onderzoek," <i>Ned. Tijdschr. Geneesk. 136(49):2428-2431, Bohn Stafleu van Loghum, Netherlands (1992) (Abstract Only in English)</i>	Abs.
	NPL248	PERRELLA, O., <i>et al.</i> , "Interleukin-10 and IFN- α in multiple sclerosis: is there a balance?" <i>J. Neurovirol. 3(Suppl 1):P17, Stockton Press, United States (1997) (Abstract Only)</i>	Abs.
	NPL249	POLMAN, C.H., <i>et al.</i> , "Diagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the "McDonald Criteria," <i>Ann. Neurol. 58(6):840-846, Wiley-Liss, Inc., United States (2005)</i>	
	NPL250	PROCHASKA, H.J. and SANTAMARIA, A.B., "Direct Measurement of NAD(P)H:Quinone Reductase from Cells Cultured in Microtiter Wells: A Screening Assay for Anticarcinogenic Enzyme Inducers," <i>Anal. Biochem. 169:328-336, Academic Press, Inc., United States (1988)</i>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	26	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL251	ROITT, I.M., <i>et al.</i> , eds., "23.Autoimmunity and Autoimmune Disease," in <i>Immunology</i> , p. 23.1-23.12, Gower Medical Publishing, United States (1985)	
	NPL252	ROSTAMI-YAZDI, M., <i>et al.</i> , "Detection of Metabolites of Fumaric Acid Esters in Human Urine: Implications for Their Mode of Action," <i>J. Invest. Dermatol.</i> 129:231-234, Nature Publishing Group, United States (2008)	
	NPL253	RUSHMORE, T.H., <i>et al.</i> , "The Antioxidant Responsive Element: Activation By Oxidative Stress And Identification of the DNA Consensus Sequence Required For Functional Activity," <i>J. Biol. Chem.</i> 266(18):11632-11639, The American Society for Biochemistry and Molecular Biology, Inc., United States (1991)	
	NPL254	Biosis Database, Accession No. PREV199699044855, English language abstract for SCHMIDT, K.N., <i>et al.</i> , "Anti-psoriatic drug anthralin activates transcription factor NF-kappa-B in murine keratinocytes," <i>J. Immunol.</i> 156(11):4514-4519, American Association of Immunologists, United States (1996) (Abstract Only)	Abs.
	NPL255	SHI, N., <i>et al.</i> , "Brain-specific expression of an exogenous gene after i.v. administration," <i>Proc. Natl. Acad. Sci. USA</i> 98(22):12754-12759, National Academy of Sciences, United States (2001)	
	NPL256	SOBEL, R.A., <i>et al.</i> "The Immunopathology Of Experimental Allergic Encephalomyelitis. I. Quantitative Analysis of Inflammatory Cells <i>In Situ</i> ," <i>J. Immunol.</i> 132(5):2393-2401, American Association of Immunologists, United States (1984)	
	NPL257	STANGEL, M., <i>et al.</i> , "Fumarat in der Behandlung der Multiplen Sklerose: Mögliche Wirkmechanismen und Studien," <i>Der Nervenarzt</i> 79:212-217, Springer Medizin Verlag, Germany (2008) (Abstract Only in English)	Abs.
	NPL258	STÜHLINGER, W., <i>et al.</i> , "Nephrotoxische Wirkung einer Therapie mit Fumarsäureestern bei Psoriasis," <i>Dtsch. Med. Wschr.</i> 115:1712-1715, Georg Thieme Verlag Stuttgart, Germany (1990) (Abstract Only in English)	Abs.
	NPL259	TRAUGOTT, U., "Detailed Analysis of Early Immunopathologic Events during Lesion Formation in Acute Experimental Autoimmune Encephalomyelitis," <i>Cell. Immunol.</i> 119:114-129, Academic Press, Inc., United States (1989)	
	NPL260	TUNG, C.-H., <i>et al.</i> , "In Vivo Imaging of Proteolytic Enzyme Activity Using a Novel Molecular Reporter," <i>Cancer Res.</i> 60:4953-4958, American Association for Cancer Research, Inc., United States (2000)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	27	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL261	TUOHY, V.K., <i>et al.</i> , "A Synthetic Peptide From Myelin Proteolipid Protein Induces Experimental Allergic Encephalomyelitis," <i>J. Immunol.</i> 141(4):1126-1130, The American Association of Immunologists, United States (1988)	
	NPL262	ÜNER, A.H., <i>et al.</i> , "Characteristics of Auto Anti-idiotypic Antibodies Reactive with Antibodies Expressing the Pathogenic Idiotype, Id ^{LN} F ₁ , in the (NZB x SWR)F ₁ Model for Lupus Nephritis and its Parental Strains," <i>J. Autoimmun.</i> 11:233-240, Academic Press, England (1998)	
	NPL263	VAN MUISWINKEL, F.L., <i>et al.</i> , "Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra," <i>Neurobiol. Aging</i> 25:1253-1262, Elsevier Inc., United States (2004)	
	NPL264	VAN MUISWINKEL, F.L. and KUIPERIJ, H.B., "The Nrf2-ARE Signalling Pathway: Promising Drug Target to Combat Oxidative Stress in Neurodegenerative Disorders," <i>Curr. Drug Targets-CNS & Neurol. Disord.</i> 4:267-281, Bentham Science Publishers Ltd., Netherlands (2005)	
	NPL265	WEINMANN, I., <i>et al.</i> , "Influence Of Fumaric Acid Derivates On T Lymphocytes In The Murine Model Of HSV-1 Keratitis," <i>Invest. Ophthalmol. Vis. Sci.</i> 41(4):S146, Association for Research in Vision and Ophthalmology annual meeting. Fort Lauderdale, Florida, USA, April 30 – May 5, 2000, United States (2000) (Abstract Only)	Abs.
	NPL266	<i>The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals</i> , 10 th Edition, p. 396, WINDHOLZ, M., <i>et al.</i> , eds., Merck & Co., Inc., United States (1983)	
	NPL267	ZAMVIL, S., <i>et al.</i> , "T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination" <i>Nature</i> 317:355-358, Nature Publishing Group, England (1985)	
	NPL268	ZAMVIL, S.S. and STEINMAN, L., "The T Lymphocyte In Experimental Allergic Encephalomyelitis," <i>Ann. Rev. Immunol.</i> 8:579-621, Annual Reviews Inc., United States (1990)	
	NPL269	Office Action mailed April 26, 2000, in U.S. Application No. 09/194,862, Joshi, R.K., <i>et al.</i> , § 371(c) date July 8, 1999 (now U.S. Patent No. 6,436,992 B1)	
	NPL270	Office Action mailed October 31, 2000, in U.S. Application No. 09/402,103, Joshi, R.K., <i>et al.</i> , § 371(c) date September 27, 1999 (now U.S. Patent No. 6,277,882 B1)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
Sheet	28	of	30	Attorney Docket Number	2159.3210002/JMC/MRG/U-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL271	Office Action mailed May 21, 2001, in U.S. Application No. 09/743,978, Joshi, R.K., <i>et al.</i> , § 371(c) date January 17, 2001 (now U.S. Pat. No. 6,355,676 B1)	
	NPL272	Office Action mailed December 7, 2001, in U.S. Application No. 09/831,620, Joshi, R.K., <i>et al.</i> , § 371(c) date May 10, 2001 (now U.S. Pat. No. 6,509,376 B1)	
	NPL273	Office Action mailed March 4, 2002, in U.S. Application No. 09/831,620, Joshi, R.K., <i>et al.</i> , § 371(c) date May 10, 2001 (now U.S. Patent No. 6,509,376 B1)	
	NPL274	Office Action mailed August 12, 2003, in U.S. Application No. 10/148,858, Joshi, R.K., <i>et al.</i> , § 371(c) date May 28, 2002 (now U.S. Patent No. 6,858,750 B2)	
	NPL275	Office Action mailed March 23, 2004, in U.S. Application No. 10/148,858, Joshi, R.K., <i>et al.</i> , § 371(c) date May 28, 2002 (now U.S. Patent No. 6,858,750 B2)	
	NPL276	Office Action mailed March 22, 2004, in U.S. Application No. 10/197,077, Joshi, R.K., <i>et al.</i> , filed July 17, 2002 (now U.S. Patent No. 7,320,999 B2)	
	NPL277	Office Action mailed November 28, 2005, in U.S. Application No. 10/197,077, Joshi, R.K., <i>et al.</i> , filed July 17, 2002 (now U.S. Patent No. 7,320,999 B2)	
	NPL278	Office Action mailed June 21, 2006, in U.S. Application No. 10/197,077, Joshi, R.K., <i>et al.</i> , filed July 17, 2002 (now U.S. Patent No. 7,320,999 B2)	
	NPL279	Office Action mailed May 15, 2007, in U.S. Application No. 10/197,077, Joshi, R.K., <i>et al.</i> , filed July 17, 2002 (now U.S. Patent No. 7,320,999 B2)	
	NPL280	Office Action mailed December 3, 2007, in U.S. Application No. 11/765,563, Joshi, R.K., <i>et al.</i> , filed June 20, 2007 (now U.S. Patent No. 7,612,110 B2)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	29	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL281	Office Action mailed September 9, 2008, in U.S. Application No. 11/765,563, Joshi, R.K., <i>et al.</i> , filed June 20, 2007 (now U.S. Patent No. 7,612,110 B2)	
	NPL282	Office Action mailed March 12, 2009, in U.S. Application No. 11/765,563, Joshi, R.K., <i>et al.</i> , filed June 20, 2007 (now U.S. Patent No. 7,612,110 B2)	
	NPL283	Office Action mailed December 14, 2007, in U.S. Application No. 11/765,578, Joshi, R.K., <i>et al.</i> , filed June 20, 2007 (now U.S. Patent No. 7,619,001 B2)	
	NPL284	Office Action mailed July 25, 2008, in U.S. Application No. 11/765,578, Joshi, R.K., <i>et al.</i> , filed June 20, 2007 (now U.S. Patent No. 7,619,001 B2)	
	NPL285	Office Action mailed September 15, 2008, in U.S. Application No. 11/765,578, Joshi, R.K., <i>et al.</i> , filed June 20, 2007 (now U.S. Patent No. 7,619,001 B2)	
	NPL286	Office Action mailed March 30, 2009, in U.S. Application No. 11/765,578, Joshi, R.K., <i>et al.</i> , filed June 20, 2007 (now U.S. Patent No. 7,619,001 B2)	
	NPL287	Office Action mailed October 2, 2009, in U.S. Application No. 12/405,661, Joshi, R.K., <i>et al.</i> , filed March 17, 2009 (now U.S. Patent No. 7,803,840 B2)	
	NPL288	Office Action notification date January 19, 2010, in U.S. Application No. 12/405,661, Joshi, R.K., <i>et al.</i> , filed March 17, 2009 (now U.S. Patent No. 7,803,840 B2)	
	NPL289	Office Action notification date May 20, 2010, in U.S. Application No. 12/405,661, Joshi, R.K., <i>et al.</i> , filed March 17, 2009 (now U.S. Patent No. 7,803,840 B2)	
	NPL290	Office Action notification date March 23, 2010, in U.S. Application No. 12/405,665, Joshi, R.K., <i>et al.</i> , filed March 17, 2009 (now U.S. Patent No. 7,915,310 B2)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known		
	Application Number	To be assigned	
	Filing Date	Herewith	
	First Named Inventor	Matvey E. LUKASHEV	
	Art Unit	To be assigned	
	Examiner Name	To be assigned	
Sheet	30	of	30
	Attorney Docket Number	2159.3210002/JMC/MRG/U-S	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL291	Office Action notification date September 9, 2010, in U.S. Application No. 12/405,665, Joshi, R.K., <i>et al.</i> , filed March 17, 2009 (now U.S. Patent No. 7,915,310 B2)	
	NPL292	English language Abstract of Chinese Patent Publication No. CN 1125141 A, European Patent Office, Espacenet database — Worldwide (Abstract Only)	Abs.
	NPL293	WALLACE, D.C., "Mitochondrial Diseases in Man and Mouse," <i>Science</i> 283:1482-1488, American Association for the Advancement of Science, United States (1999)	

1476771_1.DOCX

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
Sheet	1	of	7
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S

U.S. PATENT DOCUMENTS

Examiner initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
/J.U./	US1	4,515,974		05-07-1985	Zecher <i>et al.</i>	
/J.U./	US2	4,746,668		05-24-1988	Sato <i>et al.</i>	
/J.U./	US3	4,851,439		07-25-1989	Speiser <i>et al.</i>	
/J.U./	US4	4,959,389		09-25-1990	Speiser <i>et al.</i>	
/J.U./	US5	5,149,695		09-22-1992	Speiser <i>et al.</i>	
/J.U./	US6	5,214,196		05-25-1993	Blank	
/J.U./	US7	5,242,905		09-07-1993	Blank	
/J.U./	US8	5,359,128		10-25-1994	Blank	
/J.U./	US9	5,424,332		06-13-1995	Speiser <i>et al.</i>	
/J.U./	US10	5,451,667		09-19-1995	Speiser <i>et al.</i>	
/J.U./	US11	6,277,882 B1		08-21-2001	Joshi <i>et al.</i>	
/J.U./	US12	6,355,676 B1		03-12-2002	Joshi <i>et al.</i>	
/J.U./	US13	6,359,003 B1		03-19-2002	Joshi <i>et al.</i>	
/J.U./	US14	6,436,992 B1		08-20-2002	Joshi <i>et al.</i>	
/J.U./	US15	6,509,376 B1		01-21-2003	Joshi <i>et al.</i>	
/J.U./	US16	6,858,750 B2		02-22-2005	Joshi <i>et al.</i>	
/J.U./	US17	7,157,423 B2		01-02-2007	Joshi <i>et al.</i>	
/J.U./	US18	7,320,999 B2		01-22-2008	Joshi <i>et al.</i>	
/J.U./	US19	7,432,240 B2		10-07-2008	Joshi <i>et al.</i>	
/J.U./	US20	7,612,110 B2		11-03-2009	Joshi <i>et al.</i>	

FOREIGN PATENT DOCUMENTS

Examiner initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
/J.U./	FP1	JP 54-80439 A		06-27-1979	Ogawa Hiroe		
/J.U./	FP2	EP 0 188 749 A2		07-30-1986	Speiser <i>et al.</i>		
/J.U./	FP3	WO 89/01930 A1		03-09-1989	Dexter Biotechnics		
/J.U./	FP4	EP 0 312 697 A2		04-26-1989	Speiser <i>et al.</i>		
/J.U./	FP5	DE 38 34 794 A1		04-19-1990	Schielein, F.		
/J.U./	FP6	EP 0 518 388 A2		12-16-1992	Speiser <i>et al.</i>		
/J.U./	FP7	JP 6-345644 A		12-20-1994	Unitika Ltd.		
/J.U./	FP8	WO 94/28883 A1		12-22-1994	Brown, Raymond		

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	2	of	7		

U.S. PATENT DOCUMENTS						
Examiner initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
/J.U./	US21	7,619,001	B2	11-17-2009	Joshi <i>et al.</i>	
/J.U./	US22	7,790,916	B2	09-07-2010	Joshi <i>et al.</i>	
/J.U./	US23	7,803,840	B2	09-28-2010	Joshi <i>et al.</i>	
/J.U./	US24	7,915,310	B2	03-29-2011	Joshi <i>et al.</i>	
/J.U./	US25	2004/0054001	A1	03-18-2004	Joshi <i>et al.</i>	
/J.U./	US26	2008/0233185	A1	09-25-2008	Joshi <i>et al.</i>	
/J.U./	US27	2010/0130607	A1	05-27-2010	Gold	
/J.U./	US28	5,538,968		07-23-1996	Chiesi <i>et al.</i>	
/J.U./	US29	5,548,059		08-20-1996	Bayley <i>et al.</i>	
/J.U./	US30	5,972,363		10-26-1999	Chikeman <i>et al.</i>	
/J.U./	US31	6,812,248	B2	11-02-2004	Zhang <i>et al.</i>	
/J.U./	US32	7,056,950	B2	06-06-2006	Rath	
/J.U./	US33	7,279,331	B2	10-09-2007	Black <i>et al.</i>	
/J.U./	US34	7,364,900	B2	04-29-2008	Black <i>et al.</i>	
/J.U./	US35	7,417,045	B2	08-26-2008	Anilkumar <i>et al.</i>	
/J.U./	US36	7,638,119	B2	12-29-2009	Johnson <i>et al.</i>	
/J.U./	US37	7,871,977	B2	01-18-2011	Rischer <i>et al.</i>	
/J.U./	US38	2003/0176365	A1	09-18-2003	Blass	
/J.U./	US39	2005/0245612	A1	11-03-2005	Blass	
/J.U./	US40	2008/0089861	A1	04-17-2008	Went <i>et al.</i>	

FOREIGN PATENT DOCUMENTS							
Examiner initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		Country Code ³ -Number ⁴	Kind Code ⁵ (if known)				
/J.U./	FP9	JP	8-99906 A	04-16-1996	Chugai Pharmaceutical Co., Ltd.		
/J.U./	FP10	WO	97/09984 A1	03-20-1997	Takeda Chemical Industries, Ltd.		
/J.U./	FP11	WO	97/13504 A1	04-17-1997	Medgene Limited		
/J.U./	FP12	CA	2,248,955 A1	05-20-1997	Fumapharm AG		
/J.U./	FP13	JP	9-221428 A	08-26-1997	Fujisawa Pharmaceutical Co.		
/J.U./	FP14	WO	97/44054 A2	11-27-1997	University of Alberta		
/J.U./	FP15	WO	97/48405 A1	12-24-1997	Belyaev, Jury Evgenievich		
/J.U./	FP16	WO	98/04290 A2	02-05-1998	Perrine <i>et al.</i>		

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <h3 style="text-align: center;">FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h3> <p style="text-align: center;"><i>(Use as many sheets as necessary)</i></p>				Complete if Known	
Application Number		<i>To be assigned</i>			
Filing Date		Herewith			
First Named Inventor		Matvey E. LUKASHEV			
Art Unit		<i>To be assigned</i>			
Examiner Name		<i>To be assigned</i>			
Attorney Docket Number		2159.3210002/JMC/MRG/U-S			
Sheet	3	of	7		

U.S. PATENT DOCUMENTS						
Examiner initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				

FOREIGN PATENT DOCUMENTS							
Examiner initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
/J.U./	FP17	WO 98/27970	A2	07-02-1998	National Research Council of Canada		
/J.U./	FP18	EP 0 852 233	A1	07-08-1998	Nippon Shinyaku Company, Limited		
/J.U./	FP19	DE 197 21 099	A1	11-26-1998	Fumapharm AG		
/J.U./	FP20	WO 99/21565	A1	05-06-1999	Cornell Research Foundation, Inc.		
/J.U./	FP21	WO 01/59072	A1	08-16-2001	Philadelphia Health and Education Corporation; University of Medicine and Dentistry of New Jersey		
/J.U./	FP22	WO 02/02190	A2	01-10-2002	Johns Hopkins School of Medicine		
/J.U./	FP23	RU 2 189 813	C1	09-27-2002	Rossijskij NII Gematologii Transfuziologii		
/J.U./	FP24	WO 03/032969	A2	04-24-2003	National Research Council of Canada		

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO			Complete if Known		
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	<i>To be assigned</i>	
			Filing Date	Herewith	
			First Named Inventor	Matvey E. LUKASHEV	
			Art Unit	<i>To be assigned</i>	
			Examiner Name	<i>To be assigned</i>	
			Attorney Docket Number	2159.3210002/JMC/MRG/U-S	
Sheet	5	of	7		

U.S. PATENT DOCUMENTS

Examiner initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				

FOREIGN PATENT DOCUMENTS

Examiner initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
/J.U./	FP33	WO 95/25102 A1		09-21-1995	Novo Nordisk A/S		
/J.U./	FP34	WO 96/01122 A1		01-18-1996	Dana-Farber Cancer Institute		
/J.U./	FP35	GB 2 291 422 A		01-24-1996	Fujisawa Pharmaceutical Co., Ltd		
/J.U./	FP36	WO 96/08970 A1		03-28-1996	The Trustees of the University of Pennsylvania; Apollon, Inc.		
/J.U./	FP37	CN 1125141 A		06-26-1996	Zhongmei Huadong Pharmaceutica		
/J.U./	FP38	EP 0 793 966 A1		09-10-1997	Hanmi Pharmaceutical Co., Ltd.		
/J.U./	FP39	WO 02/38142 A2		05-16-2002	Massachusetts Institute of Technology		
/J.U./	FP40	WO 02/064129 A2		08-22-2002	Rath, Matthias		

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	To be assigned
Filing Date	Herewith
First Named Inventor	Matvey E. LUKASHEV
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2159.3210002/JMC/MRG/U-S

Sheet 6 of 7

U.S. PATENT DOCUMENTS

Examiner initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	16
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/J.U./	FP41	WO 03/020908 A2	03-13-2003	University of Medicine and Dentistry of New Jersey		
/J.U./	FP42	WO 2005/023241 A1	03-17-2005	Fumapharm AG		
/J.U./	FP43	WO 2006/088836 A2	08-24-2006	Schering Corporation; Pharmacoepia Drug Discovery, Inc.		
/J.U./	FP44	WO 2006/088837 A2	08-24-2006	Schering Corporation; Pharmacoepia Drug Discovery, Inc.		
/J.U./	FP45	WO 2006/088840 A1	08-24-2006	Schering Corporation; Pharmacoepia Drug Discovery, Inc.		
/J.U./	FP46	WO 2006/088919 A2	08-24-2006	Schering Corporation; Pharmacoepia Drug Discovery, Inc.		
/J.U./	FP47	WO 2006/088920 A1	08-24-2006	Schering Corporation; Pharmacoepia Drug Discovery, Inc.		
/J.U./	FP48	WO 2006/088921 A2	08-24-2006	Schering Corporation; Pharmacoepia Drug Discovery, Inc.		

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
Sheet	7	of	7	Attorney Docket Number	2159.3210002/JMC/MRG/U-S

U.S. PATENT DOCUMENTS						
Examiner initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				

FOREIGN PATENT DOCUMENTS							
Examiner initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
/J.U./	FP49	WO 2006/091428	A2	08-31-2006	Schering Corporation; Pharmacopeia Drug Discovery, Inc.		
/J.U./	FP50	WO 2007/042034	A1	04-19-2007	Aditech Pharma AB		

1476769_1.DOCX

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	To be assigned	
Sheet		1	of	30	Examiner Name	To be assigned
					Attorney Docket Number	2159.3210002/IMC/MRG/U-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	Thomson Innovation Patent Record, DWPI Accession No. 1979-58797B, English language Abstract of Japanese Patent Publication No. 54-80439 A, (1979)	Abs.
	NPL2	English language Abstract of German Patent Publication No. DE 38 34 794 A1, European Patent Office, Espacenet database — Worldwide (2001)	Abs.
	NPL3	English language Abstract of Japanese Patent Publication No. JP 6-345644 A, European Patent Office, Espacenet database — Worldwide (2001)	Abs.
	NPL4	English language Abstract of Japanese Patent Publication No. JP 8-99906 A, European Patent Office, Espacenet database — Worldwide (2001)	Abs.
	NPL5	English language Abstract of Japanese Patent Publication No. JP 9-221428 A, European Patent Office, Espacenet database — Worldwide (2001)	Abs.
	NPL6	English language Abstract of WIPO Patent Publication No. WO 97/48405 A1, European Patent Office, Espacenet database — Worldwide (2001)	Abs.
	NPL7	English language Abstract of Russian Patent Publication No. RU 2 189 813 C1, European Patent Office, Espacenet database — Worldwide (2002)	Abs.
	NPL8	English language Abstract of WIPO Patent Publication No. WO 2005/027899 A1, European Patent Office, Espacenet database — Worldwide (2005)	Abs.
	NPL9	ALTMAYER, P.J., <i>et al.</i> , "Antipsoriatic effect of fumaric acid derivatives Results of a multicenter double-blind study in 100 patients," <i>Journal of the American Academy of Dermatology</i> 30(6):977-981, American Academy of Dermatology, Inc., United States (1994)	
	NPL10	ANDERSSON, M., <i>et al.</i> , "Cytokine profile in interferon-β treated multiple sclerosis patients: reduction of interleukin-10 mRNA expressing cells in peripheral blood," <i>Eur. J. Neurol.</i> 4:567-571, Rapid Science Publishers, England (1997)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	2	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL11	BACHARACH-BUHLES, M., <i>et al.</i> , "Fumaric Acid Esters (FAEs) Suppress CD 15- and ODP 4-positive Cells in Psoriasis," <i>Acta. Derm. Venereol. Suppl. (Stockh)</i> 186:79-82, Scandinavian University Press, Norway (1994)	
	NPL12	BALASHOV, K.E., <i>et al.</i> , "Defective regulation of IFN γ and IL-12 by endogenous IL-10 in progressive MS," <i>Neurology</i> 55:192-198, AAN Enterprises, Inc., United States (2000)	
	NPL13	BECANOVIC, K., <i>et al.</i> , "Paradoxical effects of arthritis-regulating chromosome 4 regions on myelin oligodendrocyte glycoprotein-induced encephalomyelitis in congenic rats," <i>Eur. J. Immunol.</i> 33:1907-1916, WILEY-VCH Verlag GmbH & Co. KGaA, Germany (2003)	
	NPL14	BETTELLI, E. and NICHOLSON, L.B., "The Role of Cytokines in Experimental Autoimmune Encephalomyelitis," <i>Arch. Immun. Ther. Exp.</i> 48:389-398, Warszawa, Panstwowy Zakład Wydawn Lekarskich, Switzerland (2000)	
	NPL15	BROWN, T.R. and KRAFT, G.H., "Multiple Sclerosis: A Paradigm Shift," <i>Phys. Med. Rehabil. Clin. N. Am.</i> 16:xvii-xx, Elsevier Inc., United States (2005)	
	NPL16	CANNELLA, B., <i>et al.</i> , "IL-10 Fails to Abrogate Experimental Autoimmune Encephalomyelitis," <i>J. Neuroscience Research</i> 45:735-746, Wiley-Liss, Inc., United States (1996)	
	NPL17	CORREALE, J., <i>et al.</i> , "Sulfasalazine aggravates experimental autoimmune encephalomyelitis and causes an increase in the number of autoreactive T cells," <i>J. Neuroimmunol.</i> 34:109-120, Elsevier Science Publishers B.V., Netherlands (1991)	
	NPL18	DAHLMAN, I., <i>et al.</i> , "Quantitative trait loci disposing for both experimental arthritis and encephalomyelitis in the DA rat; impact on severity of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis and antibody isotype pattern," <i>Eur. J. Immunol.</i> 28:2188-2196, WILEY-VCH Verlag GmbH, Germany (1998)	
	NPL19	DAL CANTO, R.A., <i>et al.</i> , "Local Delivery of TNF by Retrovirus-Transduced T Lymphocytes Exacerbates Experimental Autoimmune Encephalomyelitis," <i>Clinical Immunol.</i> 90(1):10-14, Academic Press, United States (1999)	
	NPL20	DE GRAAF, K.L., <i>et al.</i> , "MHC Class II Isotype- and Allele-Specific Attenuation of Experimental Autoimmune Encephalomyelitis," <i>J. Immunol.</i> 173:2792-2802, The American Association of Immunologists, Inc., United States (2004)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	3	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL21	DE HAAN, P., "The Risk of Sensibilization and Contact Urticaria upon Topical Application of Fumaric Acid Derivatives," <i>Dermatology</i> 188:126-130, Karger AG, Switzerland (1994)	
	NPL22	DE JONG, R., <i>et al.</i> , "Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate," <i>Eur. J. Immunol.</i> 26:2067-2074, Verlag Chemie GmbH, Germany (1996)	
	NPL23	DEL PRETE, G., "The Concept of Type-1 and Type-2 Helper T Cells and Their Cytokines in Humans," <i>Intern. Rev. Immunol.</i> 16:427-455, OPA (Overseas Publishers Association) Amsterdam B.V., England (1998)	
	NPL24	DETHLEFSEN, L.A., "Toxic Effects of Acute Glutathione Depletion by Buthionine Sulfoximine and Dimethylfumarate on Murine Mammary Carcinoma Cells," <i>Radiation Res.</i> 114:215-224, Academic Press, Inc., United States (1988)	
	NPL25	DI MARCO, R., <i>et al.</i> , "Curative effects of recombinant human Interleukin-6 in DA rats with protracted relapsing experimental allergic encephalomyelitis," <i>J. Neuroimmunol.</i> 116:168-177, Elsevier Science B.V., Netherlands (2001)	
	NPL26	DI ROSA, F., <i>et al.</i> , "Lack of Th2 cytokine increase during spontaneous remission of experimental allergic encephalomyelitis," <i>Eur. J. Immunol.</i> 28:3893-3903, WILEY-VCH Verlag GmbH, Germany (1998)	
	NPL27	DJERBI, M., <i>et al.</i> , "Expression of the Long Form of Human FLIP by Retroviral Gene Transfer of Hemopoietic Stem Cells Exacerbates Experimental Autoimmune Encephalomyelitis," <i>J. Immunol.</i> 170:2064-2073, The American Association of Immunologists, Inc., United States (2003)	
	NPL28	DÜCKER, P. and PFEIFF, B., "Zwei Fälle von Nebenwirkungen einer Fumarsäureester - Lokaltharapie," <i>H+G Zeitschrift für Hautkrankheiten</i> 65:734-736, Grosse Verlag Berlin, Germany (1990) (Abstract Only in English)	Abs.
	NPL29	FERBER, I.A., <i>et al.</i> , "Mice with a Disrupted IFN- γ Gene Are Susceptible to the Induction of Experimental Autoimmune Encephalomyelitis (EAE)," <i>J. Immunol.</i> 156:5-7, The American Association of Immunologists, United States (1996)	
	NPL30	FERRANTE, P., <i>et al.</i> , "Cytokine Production and Surface Marker Expression in Acute and Stable Multiple Sclerosis: Altered IL-12 Production and Augmented Signaling Lymphocytic Activation Molecule (SLAM)-Expressing Lymphocytes in Acute Multiple Sclerosis," <i>J. Immunol.</i> 160:1514-1521, The American Association of Immunologists, United States (1998)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	4	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL31	FLIEGNER, L. and SPIEGEL, P., "Osteomalazie als offenbar seltene Nebenwirkung der oralen Fumarsäuretherapie," <i>Hautarzt</i> 43:554-560, Springer-Verlag, Germany (1992) (Abstract Only in English)	Abs.
	NPL32	FURLAN, R., <i>et al.</i> , "Interferon- β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon- γ and interleukin-4," <i>J. Neuroimmunol.</i> 111:86-92, Elsevier Science B.V., Netherlands (2000)	
	NPL33	GALLI, G., <i>et al.</i> , "Macrophage-derived chemokine production by activated human T cells <i>in vitro</i> and <i>in vivo</i> : preferential association with the production of type 2 cytokines," <i>Eur. J. Immunol.</i> 30:204-210, WILEY-VCH Verlag GmbH, Germany (2000)	
	NPL34	GASSER, M., <i>et al.</i> , "Host Vs Graft and Graft Vs Host Reactions After Allogeneic Heterotopic Small Bowel Transplantation in the Rat," <i>Transplant. Proc.</i> 24(3):1128-1129, Appleton & Lange, United States (1992)	
	NPL35	GENAIN, C.P., <i>et al.</i> , "Late Complications of Immune Deviation Therapy in a Nonhuman Primate," <i>Science</i> 274:2054-2057, American Association for the Advancement of Science, United States (1996)	
	NPL36	GHORESCHI, K. and RÖCKEN, M., "Immune Deviation Strategies in the Therapy of Psoriasis," <i>Current Drug Targets - Inflammation & Allergy</i> 3:193-198, Bentham Science Publishers Ltd., Netherlands (2004)	
	NPL37	GHORESCHI, K., <i>et al.</i> , "Fumarates induce a DC2 phenotype in dendritic cells that establishes protective Th2 responses," <i>Arch. Dermatol. Forschung</i> 296:420, Springer Verlag, Germany (2005) (Abstract Only)	Abs.
	NPL38	GHORESCHI, K., <i>et al.</i> , "Fumaric acid ester an antipsoriatic drug abolishes the capacity of T cells to induce Th1-mediated autoimmune disease," <i>Arch. Dermatol. Res.</i> 294:28, Springer Verlag, Germany (2002) (Abstract Only)	Abs.
	NPL39	GIELEN, A.W., <i>et al.</i> , "Expression of T cell immunoglobulin- and mucin-domain-containing molecules-1 and -3 (TIM-1 and -3) in the rat nervous and immune systems," <i>J. Neuroimmunol.</i> 164:93-104, Elsevier B.V., Netherlands (2005)	
	NPL40	GIJBELS, K., <i>et al.</i> , "Administration of Neutralizing Antibodies to Interleukin-6 (IL-6) Reduces Experimental Autoimmune Encephalomyelitis and Is Associated with Elevated Levels of IL-6 Bioactivity in Central Nervous System and Circulation," <i>Mol. Med.</i> 1(7):795-805, Molecular Medicine, United States (1995)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	5	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL41	GIOVANNONI, G. and MILLER, D.H., "Multiple sclerosis and its treatment," <i>J. R. Coll. Physicians Lond.</i> 33(4):315-322, Royal College of Physicians, England (1999)	
	NPL42	GUGGENMOS, J., <i>et al.</i> , "Antibody Cross-Reactivity between Myelin Oligodendrocyte Glycoprotein and the Milk Protein Butyrophilin in Multiple Sclerosis," <i>J. Immunol.</i> 172:661-668, The American Association of Immunologists, Inc., United States (2004)	
	NPL43	HEMMER, B., <i>et al.</i> , "Cytokine Phenotype of Human Autoreactive T Cell Clones Specific for the Immunodominant Myelin Basic Protein Peptide (83-99)," <i>J. Neurosci. Res.</i> 45:852-862, Wiley-Liss, Inc., United States (1996)	
	NPL44	HINTZEN, R.Q. and POLMAN, C.H., "Th-cell modulation in multiple sclerosis," <i>Immunol. Today</i> 18(10):507-508, Elsevier/North-Holland Biomedical Press, England (1997)	
	NPL45	HOHENEGGER, M., <i>et al.</i> , "Nephrotoxicity of Fumaric Acid Monoethylester (FA ME)," <i>Advances in Experimental Medicine and Biology</i> 252:265-272, Kluwer Academic, United States (1989)	
	NPL46	HULTGREN, B., <i>et al.</i> , "Genetic Absence of γ -Interferon Delays but Does Not Prevent Diabetes in NOD Mice," <i>Diabetes</i> 45:812-817, American Diabetes Association, United States (1996)	
	NPL47	English language excerpt from HUNZIKER, T. and SCHMIDLI, J., "Is Psoriasis an Autoimmune Disease?" <i>Therapeutische Umschau</i> 50:110-113, Dermatologische Klinik der Universität Bern, Switzerland (1993)	
	NPL48	HUNZIKER, T. and SCHMIDLI, J., "Psoriasis, eine Autoimmunkrankheit?" <i>Therapeutische Umschau</i> 50:110-113, Dermatologische Klinik der Universität Bern, Switzerland (1993)	
	NPL49	ISSAZADEH, S., <i>et al.</i> , "Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor α and tumor necrosis factor β ," <i>J. Neuroimmunol.</i> 61:205-212, Elsevier Science B.V, Netherlands (1995)	
	NPL50	ISSAZADEH, S., <i>et al.</i> , "Interferon γ , Interleukin 4 and Transforming Growth Factor β in Experimental Autoimmune Encephalomyelitis in Lewis Rats: Dynamics of Cellular mRNA Expression in the Central Nervous System and Lymphoid Cells," <i>J. Neurosci. Res.</i> 40:579-590, Wiley-Liss, Inc., United States (1995)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	6	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL51	ISSAZADEH, S., <i>et al.</i> , "Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor- β ," <i>J. Neuroimmunol.</i> 69:103-115, Elsevier Science B.V., Netherlands (1996)	
	NPL52	ISSAZADEH, S., <i>et al.</i> , "Major histocompatibility complex-controlled protective influences on experimental autoimmune encephalomyelitis are peptide specific," <i>Eur. J. Immunol.</i> 27:1584-1587, VCH Verlagsgesellschaft mbH, Germany (1997)	
	NPL53	KAPPOS, L., <i>et al.</i> , "Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study," <i>Lancet</i> 372:1463-1472, Lancet Publishing Group., England (2008)	
	NPL54	KHADEMI, M., <i>et al.</i> , "Induction of systemic TNF α in Natalizumab-treated multiple sclerosis," <i>Eur. J. Neurol.</i> 15:309-312, European Federation of Neurological Sciences, England (2008)	
	NPL55	KHADEMI, M., <i>et al.</i> , "Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis," <i>J. Neuroimmunol.</i> 103:202-210, Elsevier Science B.V., Netherlands (2000)	
	NPL56	KHADEMI, M., <i>et al.</i> , "T Cell Ig- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis," <i>J. Immunol.</i> 172:7169-7176, The American Association of Immunologists, Inc., United States (2004)	
	NPL57	KIEHL, R. and IONESCU, G., "A Defective Purine Nucleotide Synthesis Pathway in Psoriatic Patients," <i>Acta Derm. Venereol. (Stockh)</i> 72:253-255, Society for the Publication of Acta Dermato-Venerologica, Sweden (1992)	
	NPL58	KJELLÉN, P., <i>et al.</i> , "Genetic influence on disease course and cytokine response in relapsing experimental allergic encephalomyelitis," <i>Int. Immunol.</i> 10:333-340, Oxford University Press, England (1998)	
	NPL59	KOLBACH, D.N. and NIEBOER, C., "Fumaric acid therapy in psoriasis: Results and side effects of 2 years of treatment," <i>J. Am. Acad. Derm.</i> 27(5):769-771, Mosby, United States (1992)	
	NPL60	KRAKAUER, M., <i>et al.</i> , "Dynamic T-lymphocyte Chemokine Receptor Expression Induced by Interferon-beta Therapy in Multiple Sclerosis," <i>Scand. J. Immunol.</i> 64:155-163, Blackwell Publishing Ltd., England (2006)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	7	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL61	KRAKOWSKI, M. and OWENS, T., "Interferon- γ confers resistance to experimental allergic encephalomyelitis," <i>Eur. J. Immunol.</i> 26:1641-1646, VCH Verlagsgesellschaft mbH, Germany (1996)	
	NPL62	KURODA, K., <i>et al.</i> , "Fumaric Acid Enhances DNA Synthesis of Rat Hepatocytes by Counteracting the Toxicities of Mitomycin C and Aflatoxin B ₁ ," <i>Jpn. J. Cancer Res. (Gann)</i> 77:750-758, Japanese Cancer Association, Japan (1986)	
	NPL63	LAFAILLE, J.J., <i>et al.</i> , "Myelin Basic Protein-specific T Helper 2 (Th2) Cells Cause Experimental Autoimmune Encephalomyelitis in Immunodeficient Hosts Rather than Protect Them from the Disease," <i>J. Exp. Med.</i> 186(2):307-312, The Rockefeller University Press, United States (1997)	
	NPL64	LAFAILLE, J.J., "The Role of Helper T Cell Subsets in Autoimmune Diseases," <i>Cytokine & Growth Factor Rev.</i> 9(2):139-151, Elsevier Science Ltd., England (1998)	
	NPL65	LAHTI, A. and MAIBACH, H.I., "Contact urticaria from diethyl fumarate," <i>Contact Dermatitis</i> 12:139-140, Munksgaard, Denmark (1985)	
	NPL66	LAMAN, J.D., <i>et al.</i> , "Balancing the Th1/Th2 concept in multiple sclerosis," <i>Immunol. Today</i> 19(11):489-490, Elsevier/North-Holland Biomedical Press, England (1998)	
	NPL67	LEHNERT, S., <i>et al.</i> , "Radiation Response of Drug-Resistant Variants of a Human Breast Cancer Cell Line: The Effect of Glutathione Depletion," <i>Radiation Res.</i> 124:208-215, Academic Press, Inc., United States (1990)	
	NPL68	LIEDTKE, W., <i>et al.</i> , "Effective Treatment of Models of Multiple Sclerosis by Matrix Metalloproteinase Inhibitors," <i>Ann. Neurol.</i> 44(1):35-46, The American Neurological Association, United States (1998)	
	NPL69	LINK, J., <i>et al.</i> , "Organ-specific autoantigens induce interferon- γ and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis," <i>Neurology</i> 44:728-734, The American Academy of Neurology, United States (1994)	
	NPL70	LINK, J., <i>et al.</i> , "Organ-specific Autoantigens Induce Transforming Growth Factor- β mRNA Expression in Mononuclear Cells in Multiple Sclerosis and Myasthenia Gravis," <i>Annals Neurol.</i> 35:197-203, The American Neurological Association, United States (1994)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
Sheet	8	of	30
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL71	LINK, J., <i>et al.</i> , "Optic neuritis is associated with myelin basic protein and proteolipid protein reactive cells producing interferon- γ , interleukin-4 and transforming growth factor- β ," <i>J. Neuroimmunol.</i> 49:9-18, Elsevier Science B.V., Netherlands (1994)	
	NPL72	LINK, J., <i>et al.</i> , "Increased Transforming Growth Factor- β , Interleukin-4, and Interferon- γ in Multiple Sclerosis," <i>Ann. Neurol.</i> 36(3):379-386, The American Neurological Association, United States (1994)	
	NPL73	LINK, H., "The cytokine storm in multiple sclerosis," <i>Mult. Scler.</i> 4:12-15, Stockton Press, England (1998)	
	NPL74	LINKER, R.A., <i>et al.</i> , "Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies," <i>Expert Rev. Neurother.</i> 8(11):1683-1690, Expert Reviews Ltd., England (2008)	
	NPL75	LOBELL, A., <i>et al.</i> , "Suppressive DNA Vaccination in Myelin Oligodendrocyte Glycoprotein Peptide-Induced Experimental Autoimmune Encephalomyelitis Involves a T1-Biased Immune Response," <i>J. Immunol.</i> 170:1806-1813, The American Association of Immunologists, Inc., United States (2003)	
	NPL76	LOBELL, A., <i>et al.</i> , "Vaccination with DNA Encoding an Immunodominant Myelin Basic Protein Peptide Targeted to Fc of Immunoglobulin G Suppresses Experimental Autoimmune Encephalomyelitis," <i>J. Exp. Med.</i> 187(9):1543-1548, The Rockefeller University Press, United States (1998)	
	NPL77	LOPEZ, E., <i>et al.</i> , "Interferon γ , IL2, IL4, IL10 and TNF α Secretions in Multiple Sclerosis Patients Treated with an Anti-CD4 Monoclonal Antibody," <i>Autoimmunity</i> 29:87-92, OPA (Overseas Publishers Association) N.V., England (1999)	
	NPL78	LORENTZEN, J.C., <i>et al.</i> , "Genetic analysis of inflammation, cytokine mRNA expression and disease course of relapsing experimental autoimmune encephalomyelitis in DA rats," <i>J. Neuroimmunol.</i> 80:31-37, Elsevier Science N.V., Netherlands (1997)	
	NPL79	LORENTZEN, J.C., <i>et al.</i> , "Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant," <i>J. Neuroimmunol.</i> 63:193-205, Elsevier Science B.V., Netherlands (1995)	
	NPL80	LYONS, J.-A., <i>et al.</i> , "Pathogenesis of acute passive murine encephalomyelitis II. Th1 phenotype of the inducing population is not sufficient to cause disease," <i>J. Neuroimmunol.</i> 93:26-36, Elsevier Science B.V., Netherlands (1999)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	9	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL81	MÄÄTTÄ, J.A., <i>et al.</i> , "Neutrophils secreting tumor necrosis factor alpha infiltrate the central nervous system of BALB/c mice with experimental autoimmune encephalomyelitis," <i>J. Neuroimmunol.</i> 90:162-175, Elsevier Science B.V., Netherlands (1998)	
	NPL82	MARTIN, R., <i>et al.</i> , "T helper cell differentiation in multiple sclerosis and autoimmunity," <i>Immunol. Today</i> 19(11):495-498, Elsevier Science, England (1998)	
	NPL83	MATTNER, F., <i>et al.</i> , "Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D ₃ ," <i>Eur. J. Immunol.</i> 30:498-508, WILEY-VCH Verlag GmbH, Germany (2000)	
	NPL84	MATUSEVICIUS, D., <i>et al.</i> , "Autoantigen-induced IL-13 mRNA expression is increased in blood mononuclear cells in myasthenia gravis and multiple sclerosis," <i>Eur. J. Neurol.</i> 4:468-475, Rapid Science Publishers, England (1997)	
	NPL85	ASADULLAH, K., <i>et al.</i> , "Influence of monomethylfumarate on monocytic cytokine formation - explanation for adverse and therapeutic effects in psoriasis?" <i>Arch. Dermatol. Res.</i> 289:623-630, Springer-Verlag, Germany (1997)	
	NPL86	BACHARACH-BUHLES, M., <i>et al.</i> , "The Effect of Fumaric Acid Esters and Dithranol on Acanthosis and Hyperproliferation in Psoriasis Vulgaris," <i>Acta Derm. Venereol. (Stockh)</i> 76:190-193, Scandinavian University Press, Sweden (1996)	
	NPL87	BALASHOV, K.E., <i>et al.</i> , "Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4 ⁺ T cells via CD40 ligand," <i>Proc. Natl. Acad. Sci. USA</i> 94:599-603, The National Academy of Sciences of the United States of America, United States (1997)	
	NPL88	BARCIA, C., <i>et al.</i> , "Parkinson's Disease and Inflammatory Changes," <i>Neurotox. Res.</i> 5(6):411-418, FP Graham Publishing Co., United States (2003)	
	NPL89	BREUER, K., <i>et al.</i> , "Therapy of noninfectious granulomatous skin diseases with fumaric acid esters," <i>Br. J. Dermatol.</i> 152:1290-1295, British Association of Dermatologists, England (2005)	
	NPL90	EBERLEIN-KÖNIG, B., <i>et al.</i> , "Disseminated Granuloma Annulare - Treatment with Fumaric Acid Esters," <i>Dermatology</i> 210:223-226, S. Karger AG, Switzerland (2005)	

Examiner Signature		Date Considered	05/02/2012
-----------------------	--	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
Sheet	10	of	30
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL91	LINK, H., <i>et al.</i> , "Virus-reactive and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis," <i>J. Neuroimmunol.</i> 38:63-74, Elsevier Science Publishers B.V., Netherlands (1992)	
	NPL92	LITJENS, N.H.R., <i>et al.</i> , "Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses," <i>Eur. J. Immunol.</i> 34:565-575, WILEY-VCH Verlag GmbH & Co. KGaA, Germany (2004)	
	NPL93	LITJENS, N.H.R., <i>et al.</i> , "Pharmacokinetics of oral fumarates in healthy subjects," <i>Br. J. Clin. Pharmacol.</i> 58(4):429-432, Blackwell Publishing Ltd, England (2004)	
	NPL94	LOBELL, A., <i>et al.</i> , "Presence of CpG DNA and the Local Cytokine Milieu Determine the Efficacy of Suppressive DNA Vaccination in Experimental Autoimmune Encephalomyelitis," <i>J. Immunol.</i> 163:4754-4762, The American Association of Immunologists, United States (1999)	
	NPL95	LOEWE, R., <i>et al.</i> , "Dimethylfumarate Inhibits TNF-Induced Nuclear Entry of NF- κ B/p65 in Human Endothelial Cells," <i>J. Immunol.</i> 168:4781-4787, The American Association of Immunologists, United States (2002)	
	NPL96	LUFT, R., "The development of mitochondrial medicine," <i>Proc. Natl. Acad. Sci. USA</i> 91:8731-8738, National Academy of Sciences, United States (1994)	
	NPL97	MAYNE, M., <i>et al.</i> , "Antisense Oligodeoxynucleotide Inhibition of Tumor Necrosis Factor- α Expression Is Neuroprotective After Intracerebral Hemorrhage," <i>Stroke</i> 32:240-248, American Heart Association, Inc., United States (2001)	
	NPL98	MCGEER, P.L., <i>et al.</i> , "Expression of the histocompatibility glycoprotein HLA-DR in neurological disease," <i>Acta Neuropathol.</i> 76:550-557, Springer-Verlag, Germany (1988)	
	NPL99	MUHALLAB, S., <i>et al.</i> , "Intra-CNS activation by antigen-specific T lymphocytes in experimental autoimmune encephalomyelitis," <i>J. Neuroimmunol.</i> 113:202-211, Elsevier Science B.V., Netherlands (2001)	
	NPL100	MUSIEK, E.S., <i>et al.</i> , "Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration," <i>J. Neurochem.</i> 97:1301-1313, International Society for Neurochemistry, England (2006)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	11	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL101	MUSTAFA, M.I., <i>et al.</i> , "T cell immunity and interferon- γ secretion during experimental allergic encephalomyelitis in Lewis rats," <i>J. Neuroimmunol.</i> 31:165-177, Elsevier Science Publishers B.V., Netherlands (1991)	
	NPL102	MUSTAFA, M., <i>et al.</i> , "Immunopharmacologic Modulation of Experimental Allergic Encephalomyelitis: Low-Dose Cyclosporin-A Treatment Causes Disease Relapse and Increased Systemic T and B Cell-Mediated Myelin-Directed Autoimmunity," <i>Scand. J. Immunol.</i> 38:499-507, Blackwell Scientific Publications, England (1993)	
	NPL103	MUSTAFA, M., <i>et al.</i> , "The major histocompatibility complex influences myelin basic protein 63-88-induced T cell cytokine profile and experimental autoimmune encephalomyelitis," <i>Eur. J. Immunol.</i> 23:3089-3095, VCH Verlagsgesellschaft mbH, Germany (1993)	
	NPL104	MUSTAFA, M., <i>et al.</i> , "Protective Influences on Experimental Autoimmune Encephalomyelitis by MHC Class I and Class II Alleles," <i>J. Immunol.</i> 153:3337-3344, The American Association of Immunologists, United States (1994)	
	NPL105	NAVIKAS, V., <i>et al.</i> , "Increased mRNA Expression of IL-10 in Mononuclear Cells in Multiple Sclerosis and Optic Neuritis," <i>Scand. J. Immunol.</i> 41:171-178, Blackwell Scientific Publications, England (1995)	
	NPL106	NAVIKAS, V., <i>et al.</i> , "Augmented expression of tumour necrosis factor- α and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis," <i>Brain</i> 119:213-223, Oxford University Press, England (1996)	
	NPL107	NIBBERING, P.H., <i>et al.</i> , "Effects of Monomethylfumarate on Human Granulocytes," <i>J. Invest. Dermatol.</i> 101:37-42, The Society for Investigative Dermatology, Inc., United States (1993)	
	NPL108	NIBBERING, P.H., <i>et al.</i> , "Intracellular signalling by binding sites for the antipsoriatic agent monomethylfumarate on human granulocytes," <i>Br. J. Dermatol.</i> 137:65-75, British Association of Dermatologists, England (1997)	
	NPL109	NIEBOER, C., <i>et al.</i> , "Systemic therapy with fumaric acid derivatives: New possibilities in the treatment of psoriasis," <i>J. Am. Acad. Dermatol.</i> 20:601-608, Mosby, United States (1989)	
	NPL110	OCKENFELS, H.M., <i>et al.</i> , "The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network," <i>Br. J. Dermatol.</i> 139:390-395, British Association of Dermatologists, England (1998)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	<i>To be assigned</i>
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
				Sheet	12

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL111	OLSSON, T., <i>et al.</i> , "Autoreactive T Lymphocytes in Multiple Sclerosis Determined by Antigen-induced Secretion of Interferon- γ ," <i>J. Clin. Invest.</i> 86:981-985, The American Society for Clinical Investigation, Inc., United States (1990)	
	NPL112	OLSSON, T., "Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-gamma," <i>J. Neuroimmunol.</i> 40:211-218, Elsevier Science Publishers B.V., Netherlands (1992)	
	NPL113	OLSSON, T., <i>et al.</i> , "Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis," <i>Eur. J. Immunol.</i> 22:1083-1087, VCH Verlagsgesellschaft mbH, Germany (1992)	
	NPL114	OLSSON, T., "Cerebrospinal Fluid," <i>Ann. Neurol.</i> 36:S100-S102, American Neurological Association, United States (1994)	
	NPL115	OLSSON, T., "Role of cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis," <i>Eur. J. Neurol.</i> 1:7-19, Rapid Communications of Oxford Ltd., England (1994)	
	NPL116	OLSSON, T., "Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis," <i>Neurology</i> 45(Suppl 6):S11-S15, Lipincott Williams & Wilkins, United States (1995)	
	NPL117	OLSSON, T., <i>et al.</i> , "Genetics of rat neuroinflammation," <i>J. Neuroimmunol.</i> 107:191-200, Elsevier Science B.V., Netherlands (2000)	
	NPL118	OLSSON, T., <i>et al.</i> , "Depletion of V β 5.2/5.3 T cells with a humanized antibody in patients with multiple sclerosis," <i>Eur. J. Neurol.</i> 9:153-164, European Federation of Neurological Societies, England (2002)	
	NPL119	OLSSON, T., <i>et al.</i> , "Harm or heal - divergent effects of autoimmune neuroinflammation?" <i>TRENDS in Immunol.</i> 24(1):5-6, Elsevier Science Ltd., England (2003)	
	NPL120	PANITCH, H.S., <i>et al.</i> , "Exacerbations Of Multiple Sclerosis In Patients Treated With Gamma Interferon," <i>Lancet</i> 329:893-895, Lancet Publishing Group, England (1987)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO			Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	<i>To be assigned</i>
			Filing Date	Herewith
			First Named Inventor	Matvey E. LUKASHEV
			Art Unit	<i>To be assigned</i>
			Examiner Name	<i>To be assigned</i>
			Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	13	of	30	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL121	PEREIRA, M.A., <i>et al.</i> , "Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents," <i>Carcinogenesis</i> 15(5):1049-1054, Oxford University Press, England (1994)	
	NPL122	PETTE, M., <i>et al.</i> , "Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones," <i>J. Neuroimmunol.</i> 98:147-156, Elsevier Science B.V., Netherlands (1999)	
	NPL123	PROCHASKA, H.J., <i>et al.</i> , "Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication," <i>Proc. Natl. Acad. Sci. USA</i> 90:3953-3957, National Academy of Sciences, United States	
	NPL124	PROCHASKA, H.J., <i>et al.</i> , "Elevation of Glutathione Levels by Phase II Enzyme Inducers: Lack of Inhibition of Human Immunodeficiency Virus Type 1 Replication in Chronically Infected Monocytoid Cells," <i>Mol. Pharmacol.</i> 45:916-921, The American Society for Pharmacology and Experimental Therapeutics, United States (1994)	
	NPL125	RAO, C.V., <i>et al.</i> , "Chemoprevention of Azoxymethane-Induced Colon Cancer by Ascorbylpalmitate, Carbenoxolone, Dimethylfumarate and <i>p</i> -Methoxyphenol in Male F344 Rats," <i>Anticancer Res.</i> 15:1199-1204, Anticancer Research, Greece (1995)	
	NPL126	RAO, K.S. and MISHRA, S.H., "Antihepatotoxic activity of monomethyl fumarate isolated from <i>Fumaria indica</i> ," <i>J. Ethnopharmacol.</i> 60:207-213, Elsevier Science Ireland Ltd., Ireland (1998)	
	NPL127	RISTORI, G., <i>et al.</i> , "T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis," <i>J. Neuroimmunol.</i> 99:91-96, Elsevier Science B.V., Netherlands (1999)	
	NPL128	ROBINSON, W.H., <i>et al.</i> , "Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis," <i>Nat. Biotechnol.</i> 21(9):1033-1039, Nature Publishing Group, United States (2003)	
	NPL129	ROHOWSKY-KOCHAN, C., <i>et al.</i> , "Impaired interleukin-12 production in multiple sclerosis patients," <i>Mult. Scler.</i> 5:327-334, Stockton Press, England (1999)	
	NPL130	ROHOWSKY-KOCHAN, C., <i>et al.</i> , "Cytokine secretion profile of myelin basic protein-specific T cells in multiple sclerosis," <i>Mult. Scler.</i> 6:69-77, Macmillan Publishers Ltd., England (2000)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO			Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	<i>To be assigned</i>
			Filing Date	Herewith
			First Named Inventor	Matvey E. LUKASHEV
			Art Unit	<i>To be assigned</i>
			Examiner Name	<i>To be assigned</i>
			Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	14	of	30	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL131	ROMAGNANI, S., "The Th1/Th2 paradigm," <i>Immunol. Today</i> 18(6):263-266, Elsevier Science Ltd., England (1997)	
	NPL132	ROOK, G.A.W., <i>et al.</i> , "Bacterial vaccines for the treatment of multiple sclerosis and other autoimmune diseases," <i>Immunol. Today</i> 21(10):503-508, Elsevier Science Ltd., England (2000)	
	NPL133	SAMOILOVA, E.B., <i>et al.</i> , "Experimental Autoimmune Encephalomyelitis in Intercellular Adhesion Molecule-1-Deficient Mice," <i>Cell. Immunol.</i> 190:83-89, Academic Press, United States (1998)	
	NPL134	SEBÖK, B., <i>et al.</i> , "Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures," <i>Eur. J. Pharmacol.</i> 270:79-87, Elsevier Science B.V., Netherlands (1994)	
	NPL135	SEBÖK, B., <i>et al.</i> , "Effect of Fumaric Acid, Its Dimethylester, and Topical Antipsoriatic Drugs on Epidermal Differentiation in the Mouse Tail Model," <i>Skin Pharmacol.</i> 9:99-103, S. Karger AG, Switzerland (1996)	
	NPL136	SINGH, V.K., <i>et al.</i> , "The Paradigm of Th1 and Th2 Cytokines. Its Relevance to Autoimmunity and Allergy," <i>Immunol. Res.</i> 20:147-161, Humana Press Inc., United States (1999)	
	NPL137	SINIGAGLIA, F., <i>et al.</i> , "Type I interferons and the Th1/Th2 paradigm," <i>Dev. Comp. Immunol.</i> 23:657-663, Elsevier Science Ltd., United States (1999)	
	NPL138	SMELTZ, R.B. and SWANBORG, R.H., "Concordance and Contradiction Concerning Cytokines and Chemokines in Experimental Demyelinating Disease," <i>J. Neurosci. Res.</i> 57:147-153, Wiley-Liss, Inc., United States (1998)	
	NPL139	SÖDERSTRÖM, M., <i>et al.</i> , "T Cells Recognizing Multiple Peptides of Myelin Basic Protein are Found in Blood and Enriched in Cerebrospinal Fluid in Optic Neuritis and Multiple Sclerosis," <i>Scand. J. Immunol.</i> 37:355-368, Blackwell Scientific Publications, England (1993)	
	NPL140	SPENCER, S.R., <i>et al.</i> , "Induction of Glutathione Transferases and NAD(P)H:Quinone Reductase by Fumaric Acid Derivatives in Rodent Cells and Tissues," <i>Cancer Res.</i> 50:7871-7875, American Association for Cancer Research, United States (1990)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	15	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL141	SU, J.Y.C., <i>et al.</i> , "Reduction of H ₂ O ₂ -evoked, intracellular calcium increases in the rat N18-RE-105 neuronal cell line by pretreatment with an electrophilic antioxidant inducer," <i>Neurosci. Lett.</i> 273:109-112, Elsevier Science Ireland Ltd., Ireland (1999)	
	NPL142	SUN, J.-B., <i>et al.</i> , "Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit," <i>Proc. Natl. Acad. Sci. USA</i> 93:7196-7201, National Academy of Sciences, United States (1996)	
	NPL143	THIO, H.B., <i>et al.</i> , "Fumaric acid derivatives evoke a transient increase in intracellular free calcium concentration and inhibit the proliferation of human keratinocytes," <i>Brit. J. Dermatol.</i> 131:856-861, Blackwell Scientific Publications, England (1994)	
	NPL144	VENTEN, I., <i>et al.</i> , "Treatment of Therapy-Resistant Alopecia Areata With Fumaric Acid Esters," <i>Eur. J. Med. Res.</i> 11:300-305, I. Holzapfel Publishers, Germany (July 2006)	
	NPL145	WALLSTRÖM, E., <i>et al.</i> , "Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis," <i>J. Neurol. Sci.</i> 137:89-96, Elsevier Science B.V., Netherlands (1996)	
	NPL146	WALLSTRÖM, E., <i>et al.</i> , "Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis," <i>Eur. J. Immunol.</i> 28:3329-3335, Wiley-VCH Verlag GmbH, Germany (1998)	
	NPL147	WANG, W.Z., <i>et al.</i> , "Myelin antigen reactive T cells in cerebrovascular diseases," <i>Clin. Exp. Immunol.</i> 88:157-162, Blackwell Scientific Publications, England (1992)	
	NPL148	WEISSERT, R., <i>et al.</i> , "Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen," <i>Proc. Natl. Acad. Sci. USA</i> 97(4):1689-1694, National Academy of Sciences, United States (2000)	
	NPL149	WRIGHT, R., "Autoimmune disease of the gastro-intestinal tract," <i>Postgrad. med. J.</i> 44:765-768, BMJ Publishing Group, England (1968)	
	NPL150	ZHU, J., <i>et al.</i> , "Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome," <i>J. Neuroimmunol.</i> 84:40-52, Elsevier Science B.V., Netherlands (1998)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	16	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL151	ZIPP, F., "No Evidence for Generation of Th-2-like MBP-Specific T-Cell Lines by Blockade of the Costimulatory Molecule B7-1," <i>Scand. J. Immunol.</i> 52:510-514, Blackwell Science Ltd., England (2000)	
	NPL152	ALEXANDER, A. and WONG, S., "Graft Versus Host Disease - Pathophysiology & Management," <i>Jacksonville Medicine: Bone Marrow Transplantation</i> 51(11):1-7, Duval County Medical Society Foundation for the Duval, Clay, Nassau, St. Johns & Putnam Medical Societies, United States (2000)	
	NPL153	ANDERSON, J., <i>et al.</i> , "Aetiology of Multiple Sclerosis," <i>Br. Med. J</i> 1(5433):466-467, British Medical Association, England (1965)	
	NPL154	BROCHET, B., "[Non-specific immunosuppression and multiple sclerosis]," <i>Rev. Neurol. (Paris)</i> 154(8-9):629-634, Masson, France (1998) (Abstract Only)	Abs.
	NPL155	CALABRESE, V., <i>et al.</i> , "Acetylcarnitine Induces Heme Oxygenase in Rat Astrocytes and Protects Against Oxidative Stress: Involvement of the Transcription Factor Nrf2," <i>J. Neurosci. Res.</i> 79:509-521, Wiley-Liss, Inc., United States (2005)	
	NPL156	CHEN, X.-L. and KUNSCH, C., "Induction of Cytoprotective Genes Through Nrf2/Antioxidant Response Element Pathway: A New Therapeutic Approach for the Treatment of Inflammatory Diseases," <i>Curr. Pharm. Des.</i> 10:879-891, Bentham Science Publishers Ltd., Netherlands (2004)	
	NPL157	CORAS, B., <i>et al.</i> , "Fumaric acid esters therapy: a new treatment modality in pityriasis rubra pilaris?" <i>Br. J. Dermatol.</i> 152:388-389, British Association of Dermatologists, England (2005)	
	NPL158	FOX, R.J., "BG00012 - A Novel Oral Therapy in Development for the Treatment of Multiple Sclerosis," <i>European Neurological Review</i> 3(1):99-103, Touch Briefings, England (2008)	
	NPL159	GAMBICHLER, T., <i>et al.</i> , "Clearance of Necrobiosis lipoidica with Fumaric Acid Esters," <i>Dermatology</i> 207(4):422-424, S. Karger AG, Switzerland (2003)	
	NPL160	GAO, L., <i>et al.</i> , "Novel N-3 Fatty Acid Oxidation Products Activate Nrf2 By Destabilizing The Association Between Keap1 and Cullin3," <i>J. Biol. Chem.</i> M607622200, 18 pages, The American Society for Biochemistry and Molecular Biology, Inc., United States (November 2006)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
Sheet	17	of	30
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL161	GILGUN-SHERKI, Y., <i>et al.</i> , "The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy," <i>J. Neurol.</i> 251:261-268, Springer-Verlag, Germany (2004)	
	NPL162	GRAVES, M.C., <i>et al.</i> , "Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells," <i>Amyotroph. Lateral Scler. Other Motor Neuron Disord.</i> 5:213-219, Martin Dunitz, England (2004)	
	NPL163	GUTZMER, R., <i>et al.</i> , "Erfolgreiche Therapie einer Haut- und Lungensarkoidose mit Fumarsäureestern," <i>Hautarzt</i> 55:553-557, Springer-Verlag, Germany (2004)	
	NPL164	GUTZMER, R., <i>et al.</i> , "[Successful treatment of skin and lung sarcoidosis with fumaric acid ester]," <i>Hautarzt</i> 55:553-557, Springer-Verlag, Germany (2004) (Abstract Only)	Abs.
	NPL165	HAGEDORN, M., <i>et al.</i> , "Therapie der rezidivierenden benignen Aphthosis mit Fumarsäureestern," <i>Akt. Dermatol.</i> 31:383-387, Georg Thieme Verlag KG, Germany (2005) (Abstract Only in English)	Abs.
	NPL166	KENSLER, T.W., <i>et al.</i> , "Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway," <i>Annu. Rev. Pharmacol. Toxicol.</i> 47:6.1-6.28, Annual Reviews, United States (2007; Epub August 2006)	
	NPL167	KREUTER, A., <i>et al.</i> , "Treatment of disseminated granuloma annulare with fumaric acid esters," <i>BMC Dermatol.</i> 2(5):1-4, BioMed Central Ltd., England (2002)	
	NPL168	KREUTER, A., <i>et al.</i> , "Fumaric acid esters in necrobiosis lipoidica: results of a prospective noncontrolled study," <i>Br. J. Dermatol.</i> 153:802-807, British Association of Dermatologists, England (2005)	
	NPL169	KWAK, M.-K., <i>et al.</i> , "Enhanced Expression of the Transcription Factor Nrf2 by Cancer Chemopreventive Agents: Role of Antioxidant Response Element-Like Sequences in the <i>nrf2</i> Promoter," <i>Mol. Cell Biol.</i> 22(9):2883-2892, American Society for Microbiology, United States (2002)	
	NPL170	KWAK, M.-K., <i>et al.</i> , "Modulation of Gene Expression by Cancer Chemopreventive Dithiolethiones through the Keap1-Nrf2 Pathway," <i>J. Biol. Chem.</i> 278(10):8135-8145, The American Society for Biochemistry and Molecular Biology, Inc., United States (2003)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO			Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	<i>To be assigned</i>
			Filing Date	Herewith
			First Named Inventor	Matvey E. LUKASHEV
			Art Unit	<i>To be assigned</i>
			Examiner Name	<i>To be assigned</i>
			Attorney Docket Number	2159 3210002/JMC/MRG/U-S
Sheet	18	of	30	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T 2
	NPL171	LAHTI, A., <i>et al.</i> , "Acetylsalicylic acid inhibits non-immunologic contact urticaria," <i>Contact Dermatitis</i> 16:133-135, Munksgaard International Publishers Ltd., Denmark (1987)	
	NPL172	LEE, J.-M., <i>et al.</i> , "Identification of the NF-E2-related Factor-2-dependent Genes Conferring Protection against Oxidative Stress in Primary Cortical Astrocytes Using Oligonucleotide Microarray Analysis," <i>J. Biol. Chem.</i> 278(14):12029-12038, The American Society for Biochemistry and Molecular Biology, Inc., United States (2003)	
	NPL173	LEHMANN, J.C.U., <i>et al.</i> , "Dimethylfumarate Induces Immunosuppression via Glutathione Depletion and Subsequent Induction of Heme Oxygenase 1," <i>J. Invest. Dermatol.</i> 127:835-845, The Society for Investigative Dermatology, United States (Epub January 18, 2007)	
	NPL174	LIANG, Q., <i>et al.</i> , "Noninvasive, Repetitive, Quantitative Measurement of Gene Expression from a Bicistronic Message by Positron Emission Tomography, Following Gene Transfer with Adenovirus," <i>Mol. Ther.</i> 6(1):73-82, The American Society of Gene Therapy, United States (2002)	
	NPL175	LUKER, G.D., <i>et al.</i> , "Noninvasive Bioluminescence Imaging of Herpes Simplex Virus Type 1 Infection and Therapy in Living Mice," <i>J. Virol.</i> 76(23):12149-12161, American Society for Microbiology, United States (2002)	
	NPL176	MA, Q., <i>et al.</i> , "Multiorgan Autoimmune Inflammation, Enhanced Lymphoproliferation, and Impaired Homeostasis of Reactive Oxygen Species in Mice Lacking the Antioxidant-Activated Transcription Factor <i>Nrf2</i> ," <i>Am. J. Pathol.</i> 168(6):1960-1974, American Society for Investigative Pathology, United States (June 2006)	
	NPL177	MATTSON, M.P. and CHENG, A., "Neurohormetic phytochemicals: low-dose toxins that induce adaptive neuronal stress responses," <i>TRENDS in Neurosciences</i> 29(11):632-639, Elsevier Ltd., England (September 2006)	
	NPL178	NGUYEN, T., <i>et al.</i> , "Nrf2 Controls Constitutive and Inducible Expression of ARE-driven Genes through a Dynamic Pathway Involving Nucleocytoplasmic Shuttling by Keap1," <i>J. Biol. Chem.</i> 280(37):32485-32492, The American Society for Biochemistry and Molecular Biology, Inc., United States (2005)	
	NPL179	NIEBOER, C., <i>et al.</i> , "Fumaric Acid Therapy in Psoriasis: A Double-Blind Comparison between Fumaric Acid Compound Therapy and Monotherapy with Dimethylfumaric Acid Ester," <i>Dermatologica</i> 181:33-37, Karger AG, Switzerland (1990)	
	NPL180	NOWACK, U., <i>et al.</i> , "Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters," <i>BMC Dermatol.</i> 2(15):1-5, BioMed Central Ltd., England (2002)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
Sheet	19	of	30	Attorney Docket Number	2159.3210002/JMC/MRG/U-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL181	O'GARRA, A., <i>et al.</i> , "CD4 ⁺ T-cell subsets in autoimmunity," <i>Curr. Opin. Immunol.</i> 9:872-883, Current Biology Ltd., England (1997)	
	NPL182	OLSSON, T., <i>et al.</i> , "Chapter 22: MHC and Non-MHC Genetics of Experimental Autoimmune Encephalomyelitis," in <i>From Basic Immunology to Immune-Mediated Demyelination</i> , Martino, G. and Adorini, L., eds., p. 246-264, Springer-Verlag, Italy (1999)	
	NPL183	OLSSON, T., "Critical Influences of the Cytokine Orchestration on the Outcome of Myelin Antigen-Specific T-Cell Autoimmunity in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis," <i>Immunol. Rev.</i> 144:245-268, Munksgaard, Denmark (1995)	
	NPL184	PASHENKOV, M., <i>et al.</i> , "Recruitment of dendritic cells to the cerebrospinal fluid in bacterial neuroinfections," <i>J. Neuroimmunol.</i> 122:106-116, Elsevier Science B.V., Netherlands (2002)	
	NPL185	PERMANA, P.A., <i>et al.</i> , "Macrophage-secreted factors induce adipocyte inflammation and insulin resistance," <i>Biochem. Biophys. Res. Commun.</i> 341:507-514, Elsevier Inc., United States (Epub January 2006)	
	NPL186	PETTE, M., <i>et al.</i> , "In vitro modulation of human, autoreactive MBP-specific CD4 + T-cell clones by cyclosporin A," <i>J. Neuroimmunol.</i> 76:91-99, Elsevier Science B.V., Netherlands (1997)	
	NPL187	ROODNAT, J.I., <i>et al.</i> , "Akute Niereninsuffizienz bei der Behandlung der Psoriasis mit Fumarsäure-Estern," <i>Schweiz. med. Wschr.</i> 119:826-830, Basel, B. Schwabe & Co., Switzerland (1989) (Abstract Only in English)	Abs.
	NPL188	RUDGE, P., "Cyclosporine and multiple sclerosis: The cons," <i>Neurology</i> 38(7)(Suppl 2):29-30, Lippincott Williams & Wilkins, United States (1988)	
	NPL189	RUULS, S.R., <i>et al.</i> , "The Length of Treatment Determines Whether IFN- β Prevents or Aggravates Experimental Autoimmune Encephalomyelitis in Lewis Rats," <i>J. Immunol.</i> 157:5721-5731, The American Association of Immunologists, United States (1996)	
	NPL190	SATOH, T., <i>et al.</i> , "Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic phase II inducers," <i>Proc. Natl. Acad. Sci. USA</i> 103(3):768-773, The National Academy of Sciences of the USA, United States (January 2006)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	20	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL191	SCHILLING, F. and SCHOPF, R.E., "Adultes Debré-de Toni-Fanconi-Syndrom mit Osteomalazie, erworben durch Langzeittherapie einer Psoriasis mit Fumarsäureester - zugleich ein Beitrag zur malazischen Osteoarthropathie," <i>Akt. Rheumatol.</i> 24(6):174-179, Georg Thieme Verlag, Germany (1999) (Abstract Only in English)	Abs.
	NPL192	SCHILLING, S., <i>et al.</i> , "Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration," <i>Clin. Exp. Immunol.</i> 145:101-107, British Society for Immunology, England (2006)	
	NPL193	SCHWINGHAMMER, T.L. and BLOOM, E.J., "Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation," <i>Clinical Pharm.</i> 12:736-761, American Society of Hospital Pharmacists, Inc., United States (1993)	
	NPL194	SHIH, A.Y., <i>et al.</i> , "A Small-Molecule-Inducible Nrf2-Mediated Antioxidant Response Provides Effective Prophylaxis against Cerebral Ischemia <i>In Vivo</i> ," <i>J. Neurosci.</i> 25(44):10321-10335, Society for Neuroscience, United States (2005)	
	NPL195	SUMMERS, S.A., "Ceramide in insulin resistance and lipotoxicity," <i>Prog. Lipid Res.</i> 45:42-72, Elsevier Ltd., England (January 2006; Epub December 2005)	
	NPL196	THIMMULAPPA, R.K., <i>et al.</i> , "Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis," <i>J. Clin. Invest.</i> 116(4):984-995, American Society for Clinical Investigation, United States (April 2006)	
	NPL197	VAN HORSEN, J., <i>et al.</i> , "NAD(P)H:quinone oxidoreductase 1 expression in multiple sclerosis lesions," <i>Free Radic. Biol. Med.</i> 41:311-317, Elsevier Inc., United States (Epub April 2006)	
	NPL198	VAN LOENEN, A.C., <i>et al.</i> , "Fumaarzuurtherapie: van fictie tot werkelijkheid?" <i>Pharm. Weekbl.</i> 124:894-900, D B Centens Witgeversmij, Netherlands (1989) (Abstract Only in English)	Abs.
	NPL199	VANDERMEEREN, M., <i>et al.</i> , "Dimethylfumarate Is an Inhibitor of Cytokine-Induced E-Selection, VCAM-1, and ICAM-1 Expression in Human Endothelial Cells," <i>Biochem. Biophys. Res. Comm.</i> 234:19-23, Academic Press, United States (1997)	
	NPL200	VANDERMEEREN, M., <i>et al.</i> , "Dimethylfumarate is an Inhibitor of Cytokine-Induced Nuclear Translocation of NF-κB1, But Not RelA in Normal Human Dermal Fibroblast Cells," <i>J. Invest. Dermatol.</i> 116:124-130, The Society for Investigative Dermatology, Inc., United States (2001)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	21	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL201	WAKABAYASHI, N., <i>et al.</i> , "Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation," <i>Nat. Genet.</i> 35(3):238-245, Nature Publishing Group, United States (2003)	
	NPL202	WANSCHER, B. and SØRENSEN, P.S., "Nye behandlingsmuligheder for dissemineret sklerose?" <i>Ugeskr Læger</i> 156(43):6353-6358, Den Alm Danske Laegerforening, Denmark (1994) (Abstract Only in English)	Abs.
	NPL203	WERDENBERG, D., <i>et al.</i> , "Presystemic Metabolism and Intestinal Absorption of Antipsoriatic Fumaric Acid Esters," <i>Biopharm. Drug Dispos.</i> 24(6):259-273, John Wiley & Sons, Ltd., England (2003)	
	NPL204	WERDENBERG, D., <i>Stability, Permeability and Pharmacokinetics of Perorally Administered Fumarates</i> , Doctoral Dissertation submitted to the Swiss Federal Institute of Technology Zurich, pp. 86, 87, 90, 125 (2003)	
	NPL205	ZHU, K. and MROWIETZ, U., "Inhibition of Dendritic Cell Differentiation by Fumaric Acid Esters," <i>J. Invest. Dermatol.</i> 116:203-208, The Society for Investigative Dermatology, Inc., United States (2001)	
	NPL206	The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, "TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study," <i>Neurol.</i> 53:457-465, American Academy of Neurology, United States (1999)	
	NPL207	"Oral Compound BG-12 Achieves Primary Endpoint in Phase II Study of Relapsing-Remitting Multiple Sclerosis; Treatment with BG-12 Led to Statistically Significant Reductions in MRI Measures," Biogen Idec, accessed at http://phx.corporate-ir.net/staging/phoenix.zhtml?c=148682&p=irol-newsArticle_print&ID=861749&highlight , published online May 30, 2006, 2 pages	
	NPL208	"Phase II Study of Oral Compound BG-12 Meets Primary Endpoint in Multiple Sclerosis," Biogen Idec, accessed at http://phx.corporate-ir.net/staging/phoenix.zhtml?c=148682&p=irol-newsArticle_print&ID=801882&highlight , published online January 9, 2006, 1 page	
	NPL209	"Polyarthritis," Wikipedia.org, accessed at www.en.wikipedia.org/wiki/Polyarthritis , accessed on September 3, 2008, 4 pages	
	NPL210	<i>Immunomodulation durch Fumaderm. Das richtungsweisende Konzept</i> , Charite-Berlin Hautklinik Symposium, November 1-3, 1996, p. 1-27	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	22	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL211	Partial English language translation, 4 pages, of <i>Immunomodulation durch Fumaderm. Das richtungsweisende Konzept</i> , Charite-Berlin Hautklinik Symposium, November 1-3, 1996, p. 1-27	
	NPL212	ANDO, D.G., <i>et al.</i> , "Encephalitogenic T Cells in the B10.PL Model of Experimental Allergic Encephalomyelitis (EAE) Are of the Th-1 Lymphokine Subtype," <i>Cell. Immunol.</i> 124:132-143, Academic Press, Inc., United States (1989)	
	NPL213	BAKER, D., <i>et al.</i> , "Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice," <i>J. Neuroimmunol.</i> 28(3):261-270, Elsevier Science Publishers B.V. (Biomedical Division), Netherlands, (1990)	
	NPL214	BAXTER, A.G., <i>et al.</i> , "High And Low Diabetes Incidence Nonobese Diabetic (NOD) Mice: Origins And Characterisation," <i>Autoimmunity</i> 9:61-67, Harwood Academic Publishers GmbH, England (1991)	
	NPL215	BAYARD, W., <i>et al.</i> , "Perorale Langzeitbehandlung der Psoriasis mit Fumarsäurederivaten" <i>Hautarzt</i> 38:279-285, Springer-Verlag, Germany (1987) (Abstract Only in English)	Abs.
	NPL216	BEN-NUN, A., <i>et al.</i> , "The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis," <i>Eur. J. Immunol.</i> 11:195-199, Verlag Chemie, GmbH, Germany (1981)	
	NPL217	BUTTER, C., <i>et al.</i> , "Mononuclear cell trafficking and plasma protein extravasation into the CNS during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice," <i>J. Neurol. Sci.</i> 104:9-12, Elsevier Science Publishers B.V., Netherlands (1991)	
	NPL218	DINKOVA-KOSTOVA, A.T., <i>et al.</i> , "Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups," <i>Proc. Natl. Acad. Sci. USA</i> 98(6):3404-3409, National Academy of Sciences, United States (2001)	
	NPL219	<i>Encyclopedia of Molecular Biology and Molecular Medicine</i> , Meyers, R.A., ed., p. 343, VCH Verlagsgesellschaft mbH, Germany (1996)	
	NPL220	ERCOLINI, A.M. and MILLER, S.D., "Mechanisms of Immunopathology in Murine Models of Central Nervous System Demyelinating Disease," <i>J. Immunol.</i> 176(6):3293-3298, The American Association of Immunologists, Inc., United States (March 2006)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	23	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL221	EUGSTER, H.-P., <i>et al.</i> , "Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1," <i>Eur. J. Immunol.</i> 29:626-632, WILEY-VCH Verlag GmbH, Germany (1999)	
	NPL222	FREIREICH, E.J., <i>et al.</i> , "Quantitative Comparison Of Toxicity Of Anticancer Agents In Mouse, Rat, Hamster, Dog, Monkey, And Man," <i>Cancer Chemother. Reports</i> 50(4):219-244, National Cancer Institute, United States (1966)	
	NPL223	FRIEDRICH, M., <i>et al.</i> , "Addition of Pentoxifylline Could Reduce the Side Effects of Fumaric Acid Esters in the Treatment of Psoriasis," <i>Acta Derm. Venereol.</i> 81:429-430, Taylor & Francis, Sweden (2001)	
	NPL224	GOLD, R., <i>et al.</i> , "Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research," <i>Brain</i> 129:1953-1971, Oxford University Press, England (August 2006)	
	NPL225	HABIG, W.H., <i>et al.</i> , "Glutathione S-Transferases: The First Enzymatic Step in Mercapturic Acid Formation," <i>J. Biol. Chem.</i> 249(22):7130-7139, The American Society for Biological Chemists, Inc., United States (1974)	
	NPL226	HARRIS, J.O., <i>et al.</i> , "Serial Gadolinium-enhanced Magnetic Resonance Imaging Scans in Patients with Early, Relapsing-Remitting Multiple Sclerosis: Implications for Clinical Trials and Natural History," <i>Ann. Neurol.</i> 29:548-555, American Neurological Association, United States (1991)	
	NPL227	HARTUNG, H.-P., <i>et al.</i> , "The Role Of Macrophages And Eicosanoids In The Pathogenesis Of Experimental Allergic Neuritis," <i>Brain</i> 111:1039-1059, Oxford University Press, England (1988)	
	NPL228	HEMMINKI, A., <i>et al.</i> , "In Vivo Molecular Chemotherapy and Noninvasive Imaging With an Infectivity-Enhanced Adenovirus," <i>J. Natl. Cancer Inst.</i> 94(10):741-749, Oxford University Press, United States (2002)	
	NPL229	Jl, H., <i>et al.</i> , "Different modes of pathogenesis in T-cell-dependent autoimmunity: clues from two TCR transgenic systems," <i>Immunol. Rev.</i> 169:139-146, Munksgaard International Publishers, Denmark (1999)	
	NPL230	KAPPOS, L., <i>et al.</i> , "Efficacy of a novel oral single-agent Fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase II study," oral presentation on May 30, 2006, at the 16th Meeting of the European Neurological Society, May 27-31, 2006, Lausanne, Switzerland	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO			<p align="center">Complete if Known</p>	
<p align="center">FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p align="center"><i>(Use as many sheets as necessary)</i></p>			Filing Date	Herewith
			First Named Inventor	Matvey E. LUKASHEV
			Art Unit	To be assigned
			Examiner Name	To be assigned
			Attorney Docket Number	2159.3210002/IMC/MRG/U-S
			Sheet	24

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL231	KAPPOS, L., <i>et al.</i> , "Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study," Abstract O108, Proceedings of the 16th Meeting of the European Neurological Society, May 27-31, 2006, Lausanne, Switzerland (Abstract Only)	Abs.
	NPL232	KAPPOS, L., <i>et al.</i> , "The Efficacy of BG00012 in Patients With Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses From the Phase 2b Study," poster from the 60th Annual Meeting of the American Academy of Neurology, April 12-19, 2008, Chicago, IL, United States	
	NPL233	KERMODE, A.G., <i>et al.</i> , "Breakdown Of The Blood-Brain Barrier Precedes Symptoms And Other MRI Signs Of New Lesions In Multiple Sclerosis," <i>Brain</i> 113:1477-1489, Oxford University Press, England (1990)	
	NPL234	Klinische Studie mit Fumadem[®] als magensaftresistente Mikrotabletten Report, 11 pages	
	NPL235	KURODA, K. and AKAO, M., "Antitumor And Anti-Intoxication Activities Of Fumaric Acid In Cultured Cells," <i>Gann</i> . 72(5):777-782, Japanese Cancer Association and the Japanese Foundation for Cancer Research, Japan (1981)	
	NPL236	Biosis Database, Accession No. PREV197662032843, English language abstract for KURODA, K., <i>et al.</i> , "Inhibitory Effect Of Capsella-Bursa-Pastoris Extract On Growth Of Ehrlich Solid Tumor In Mice," <i>Cancer Res.</i> 36(6):1900-1903, American Association for Cancer Research, United States (1976) (Abstract Only)	Abs.
	NPL237	LINKER, R.A., <i>et al.</i> , "CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation," <i>Nature Medicine</i> 8(6):620-624, Nature America Inc., United States (2002)	
	NPL238	LODIE, T.A., <i>et al.</i> , "Systematic Analysis of Reportedly Distinct Populations of Multipotent Bone Marrow-Derived Stem Cells Reveals a Lack of Distinction," <i>Tissue Eng.</i> 8(5):739-751, Mary Ann Liebert, Inc., United States (2002)	
	NPL239	MENDEL, I., <i>et al.</i> , "A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2 ^b mice: fine specificity and T cell receptor Vβ expression of encephalitogenic T cells," <i>Eur. J. Immunol.</i> 25:1951-1959, VCH Verlagsgesellschaft mbH, Germany (1995)	
	NPL240	<i>The Merck Manual of Diagnosis and Therapy</i> , 15 th Edition, Berkow, R. and Fletcher, A.J., eds., p. 327, Merck Sharp & Dohme Research Lab, United States (1987)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	25	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL241	NIEBOER, C., <i>et al.</i> , "Treatment of psoriasis with fumaric acid derivates," <i>Proceedings of the 239th Meeting of the Netherlands Society for Dermatology and Venereology Amsterdam, 14 February 1987, Br. J. Dermatol. 117(6):791-92, Blackwell Scientific Publications, England (1987) (Abstract Only)</i>	Abs.
	NPL242	NIOI, P. and HAYES, J.D., "Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors," <i>Mutat. Res. 555:149-171, Elsevier B.V., Netherlands (2004)</i>	
	NPL243	OLSSON, T., "15: Future prospects of cytokines in the pathogenesis and management of multiple sclerosis," in <i>Frontiers in Multiple Sclerosis, Volume 2</i> , p. 139-150, Siva, A., <i>et al.</i> , eds., Martin Dunitz Ltd., England (1999)	
	NPL244	OLSSON, T., "Chapter 6: Cytokines in Multiple Sclerosis and Its Experimental Models," in <i>Neuroscience Intelligence Unit 5: T-Cell Autoimmunity and Multiple Sclerosis</i> , Londei, M., ed., p. 91-112, R.G. Landes Company, United States (1999)	
	NPL245	Biosis Database, Accession No. PREV199497368291, English language abstract for PEARL, J.M., <i>et al.</i> , "Fumarate-enriched blood cardioplegia results in complete functional recovery of immature myocardium," <i>Ann. Thorac. Surg. 57(6):1636-1641, Elsevier, Netherlands (1994) (Abstract Only)</i>	Abs.
	NPL246	PEETERS, A.J., <i>et al.</i> , "Fumaric Acid Therapy for Psoriatic Arthritis. A Randomized, Double-blind, Placebo-controlled Study," <i>Br. J. Rheumatol. XXXI(7):502-504, British Association for Rheumatology and Rehabilitation, England (1992)</i>	
	NPL247	PEETERS, A.J., <i>et al.</i> , "Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo-gecontroleerd onderzoek," <i>Ned. Tijdschr. Geneesk. 136(49):2428-2431, Bohn Stafleu van Loghum, Netherlands (1992) (Abstract Only in English)</i>	Abs.
	NPL248	PERRELLA, O., <i>et al.</i> , "Interleukin-10 and IFN- α in multiple sclerosis: is there a balance?" <i>J. Neurovirol. 3(Suppl 1):P17, Stockton Press, United States (1997) (Abstract Only)</i>	Abs.
	NPL249	POLMAN, C.H., <i>et al.</i> , "Diagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the "McDonald Criteria," <i>Ann. Neurol. 58(6):840-846, Wiley-Liss, Inc., United States (2005)</i>	
	NPL250	PROCHASKA, H.J. and SANTAMARIA, A.B., "Direct Measurement of NAD(P)H:Quinone Reductase from Cells Cultured in Microtiter Wells: A Screening Assay for Anticarcinogenic Enzyme Inducers," <i>Anal. Biochem. 169:328-336, Academic Press, Inc., United States (1988)</i>	

Examiner Signature	/John Uim/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
				Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	26	of	30		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL251	ROITT, I.M., <i>et al.</i> , eds., "23. Autoimmunity and Autoimmune Disease," in <i>Immunology</i> , p. 23.1-23.12, Gower Medical Publishing, United States (1985)	
	NPL252	ROSTAMI-YAZDI, M., <i>et al.</i> , "Detection of Metabolites of Fumaric Acid Esters in Human Urine: Implications for Their Mode of Action," <i>J. Invest. Dermatol.</i> 129:231-234, Nature Publishing Group, United States (2008)	
	NPL253	RUSHMORE, T.H., <i>et al.</i> , "The Antioxidant Responsive Element: Activation By Oxidative Stress And Identification of the DNA Consensus Sequence Required For Functional Activity," <i>J. Biol. Chem.</i> 266(18):11632-11639, The American Society for Biochemistry and Molecular Biology, Inc., United States (1991)	
	NPL254	Biosis Database, Accession No. PREV199699044855, English language abstract for SCHMIDT, K.N., <i>et al.</i> , "Anti-psoriatic drug anthralin activates transcription factor NF-kappa-B in murine keratinocytes," <i>J. Immunol.</i> 156(11):4514-4519, American Association of Immunologists, United States (1996) (Abstract Only)	Abs.
	NPL255	SHI, N., <i>et al.</i> , "Brain-specific expression of an exogenous gene after i.v. administration," <i>Proc. Natl. Acad. Sci. USA</i> 98(22):12754-12759, National Academy of Sciences, United States (2001)	
	NPL256	SOBEL, R.A., <i>et al.</i> "The Immunopathology Of Experimental Allergic Encephalomyelitis. I. Quantitative Analysis of Inflammatory Cells <i>In Situ</i> ," <i>J. Immunol.</i> 132(5):2393-2401, American Association of Immunologists, United States (1984)	
	NPL257	STANGEL, M., <i>et al.</i> , "Fumarat in der Behandlung der Multiplen Sklerose: Mögliche Wirkmechanismen und Studien," <i>Der Nervenarzt</i> 79:212-217, Springer Medizin Verlag, Germany (2008) (Abstract Only in English)	Abs.
	NPL258	STÜHLINGER, W., <i>et al.</i> , "Nephrotoxische Wirkung einer Therapie mit Fumarsäureestern bei Psoriasis," <i>Dtsch. Med. Wschr.</i> 115:1712-1715, Georg Thieme Verlag Stuttgart, Germany (1990) (Abstract Only in English)	Abs.
	NPL259	TRAUGOTT, U., "Detailed Analysis of Early Immunopathologic Events during Lesion Formation in Acute Experimental Autoimmune Encephalomyelitis," <i>Cell. Immunol.</i> 119:114-129, Academic Press, Inc., United States (1989)	
	NPL260	TUNG, C.-H., <i>et al.</i> , "In Vivo Imaging of Proteolytic Enzyme Activity Using a Novel Molecular Reporter," <i>Cancer Res.</i> 60:4953-4958, American Association for Cancer Research, Inc., United States (2000)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
Sheet	27	of	30	Attorney Docket Number	2159.3210002/JMC/MRG/U-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL261	TUOHY, V.K., <i>et al.</i> , "A Synthetic Peptide From Myelin Proteolipid Protein Induces Experimental Allergic Encephalomyelitis," <i>J. Immunol.</i> 141(4):1126-1130, The American Association of Immunologists, United States (1988)	
	NPL262	UNER, A.H., <i>et al.</i> , "Characteristics of Auto Anti-idiotypic Antibodies Reactive with Antibodies Expressing the Pathogenic Idiotype, Id ^{NF1} , in the (NZB x SWR)F ₁ Model for Lupus Nephritis and its Parental Strains," <i>J. Autoimmun.</i> 11:233-240, Academic Press, England (1998)	
	NPL263	VAN MUISWINKEL, F.L., <i>et al.</i> , "Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra," <i>Neurobiol. Aging</i> 25:1253-1262, Elsevier Inc., United States (2004)	
	NPL264	VAN MUISWINKEL, F.L. and KUIPERIJ, H.B., "The Nrf2-ARE Signalling Pathway: Promising Drug Target to Combat Oxidative Stress in Neurodegenerative Disorders," <i>Curr. Drug Targets-CNS & Neurol. Disord.</i> 4:267-281, Bentham Science Publishers Ltd., Netherlands (2005)	
	NPL265	WEINMANN, I., <i>et al.</i> , "Influence Of Fumaric Acid Derivates On T Lymphocytes In The Murine Model Of HSV-1 Keratitis," <i>Invest. Ophthalmol. Vis. Sci.</i> 41(4):S146, Association for Research in Vision and Ophthalmology annual meeting. Fort Lauderdale, Florida, USA, April 30 – May 5, 2000, United States (2000) (Abstract Only)	Abs.
	NPL266	<i>The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals</i> , 10 th Edition, p. 396, WINDHOLZ, M., <i>et al.</i> , eds., Merck & Co., Inc., United States (1983)	
	NPL267	ZAMVIL, S., <i>et al.</i> , "T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination" <i>Nature</i> 317:355-358, Nature Publishing Group, England (1985)	
	NPL268	ZAMVIL, S.S. and STEINMAN, L., "The T Lymphocyte In Experimental Allergic Encephalomyelitis," <i>Ann. Rev. Immunol.</i> 8:579-621, Annual Reviews Inc., United States (1990)	
	NPL269	Office Action mailed April 26, 2000, in U.S. Application No. 09/194,862, Joshi, R.K., <i>et al.</i> , § 371(c) date July 8, 1999 (now U.S. Patent No. 6,436,992 B1)	
	NPL270	Office Action mailed October 31, 2000, in U.S. Application No. 09/402,103, Joshi, R.K., <i>et al.</i> , § 371(c) date September 27, 1999 (now U.S. Patent No. 6,277,882 B1)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	28	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL271	Office Action mailed May 21, 2001, in U.S. Application No. 09/743,978, Joshi, R.K., <i>et al.</i> , § 371(c) date January 17, 2001 (now U.S. Pat. No. 6,355,676 B1)	
	NPL272	Office Action mailed December 7, 2001, in U.S. Application No. 09/831,620, Joshi, R.K., <i>et al.</i> , § 371(c) date May 10, 2001 (now U.S. Pat. No. 6,509,376 B1)	
	NPL273	Office Action mailed March 4, 2002, in U.S. Application No. 09/831,620, Joshi, R.K., <i>et al.</i> , § 371(c) date May 10, 2001 (now U.S. Patent No. 6,509,376 B1)	
	NPL274	Office Action mailed August 12, 2003, in U.S. Application No. 10/148,858, Joshi, R.K., <i>et al.</i> , § 371(c) date May 28, 2002 (now U.S. Patent No. 6,858,750 B2)	
	NPL275	Office Action mailed March 23, 2004, in U.S. Application No. 10/148,858, Joshi, R.K., <i>et al.</i> , § 371(c) date May 28, 2002 (now U.S. Patent No. 6,858,750 B2)	
	NPL276	Office Action mailed March 22, 2004, in U.S. Application No. 10/197,077, Joshi, R.K., <i>et al.</i> , filed July 17, 2002 (now U.S. Patent No. 7,320,999 B2)	
	NPL277	Office Action mailed November 28, 2005, in U.S. Application No. 10/197,077, Joshi, R.K., <i>et al.</i> , filed July 17, 2002 (now U.S. Patent No. 7,320,999 B2)	
	NPL278	Office Action mailed June 21, 2006, in U.S. Application No. 10/197,077, Joshi, R.K., <i>et al.</i> , filed July 17, 2002 (now U.S. Patent No. 7,320,999 B2)	
	NPL279	Office Action mailed May 15, 2007, in U.S. Application No. 10/197,077, Joshi, R.K., <i>et al.</i> , filed July 17, 2002 (now U.S. Patent No. 7,320,999 B2)	
	NPL280	Office Action mailed December 3, 2007, in U.S. Application No. 11/765,563, Joshi, R.K., <i>et al.</i> , filed June 20, 2007 (now U.S. Patent No. 7,612,110 B2)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	<i>To be assigned</i>
		Filing Date	Herewith
		First Named Inventor	Matvey E. LUKASHEV
		Art Unit	<i>To be assigned</i>
		Examiner Name	<i>To be assigned</i>
		Attorney Docket Number	2159.3210002/JMC/MRG/U-S
Sheet	29	of	30

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL281	Office Action mailed September 9, 2008, in U.S. Application No. 11/765,563, Joshi, R.K., <i>et al.</i> , filed June 20, 2007 (now U.S. Patent No. 7,612,110 B2)	
	NPL282	Office Action mailed March 12, 2009, in U.S. Application No. 11/765,563, Joshi, R.K., <i>et al.</i> , filed June 20, 2007 (now U.S. Patent No. 7,612,110 B2)	
	NPL283	Office Action mailed December 14, 2007, in U.S. Application No. 11/765,578, Joshi, R.K., <i>et al.</i> , filed June 20, 2007 (now U.S. Patent No. 7,619,001 B2)	
	NPL284	Office Action mailed July 25, 2008, in U.S. Application No. 11/765,578, Joshi, R.K., <i>et al.</i> , filed June 20, 2007 (now U.S. Patent No. 7,619,001 B2)	
	NPL285	Office Action mailed September 15, 2008, in U.S. Application No. 11/765,578, Joshi, R.K., <i>et al.</i> , filed June 20, 2007 (now U.S. Patent No. 7,619,001 B2)	
	NPL286	Office Action mailed March 30, 2009, in U.S. Application No. 11/765,578, Joshi, R.K., <i>et al.</i> , filed June 20, 2007 (now U.S. Patent No. 7,619,001 B2)	
	NPL287	Office Action mailed October 2, 2009, in U.S. Application No. 12/405,661, Joshi, R.K., <i>et al.</i> , filed March 17, 2009 (now U.S. Patent No. 7,803,840 B2)	
	NPL288	Office Action notification date January 19, 2010, in U.S. Application No. 12/405,661, Joshi, R.K., <i>et al.</i> , filed March 17, 2009 (now U.S. Patent No. 7,803,840 B2)	
	NPL289	Office Action notification date May 20, 2010, in U.S. Application No. 12/405,661, Joshi, R.K., <i>et al.</i> , filed March 17, 2009 (now U.S. Patent No. 7,803,840 B2)	
	NPL290	Office Action notification date March 23, 2010, in U.S. Application No. 12/405,665, Joshi, R.K., <i>et al.</i> , filed March 17, 2009 (now U.S. Patent No. 7,915,310 B2)	

Examiner Signature	/John Ulm/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	<i>To be assigned</i>
				Filing Date	Herewith
				First Named Inventor	Matvey E. LUKASHEV
				Art Unit	<i>To be assigned</i>
				Examiner Name	<i>To be assigned</i>
Sheet	30	of	30	Attorney Docket Number	2159.3210002/JMC/MRG/U-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL291	Office Action notification date September 9, 2010, in U.S. Application No. 12/405,665, Joshi, R.K., <i>et al.</i> , filed March 17, 2009 (now U.S. Patent No. 7,915,310 B2)	
	NPL292	English language Abstract of Chinese Patent Publication No. CN 1125141 A European Patent Office, Espacenet database — Worldwide (Abstract Only)	Abs.
	NPL293	WALLACE, D.C., "Mitochondrial Diseases in Man and Mouse," <i>Science</i> 283:1482-1488, American Association for the Advancement of Science, United States (1999)	

1476771_1.DOCX

Examiner Signature	/John Uim/	Date Considered	05/02/2012
-----------------------	------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.